



EUROPEAN PSYCHIATRIC ASSOCIATION

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

Madrid, Spain 12-15 March 2016  
[www.epa-congress.org](http://www.epa-congress.org)

TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY



Scan this code with your smart phone  
[www.epa-congress.org](http://www.epa-congress.org)  
Need a code reader for your phone?  
<http://get.neoreader.com>



EUROPEAN PSYCHIATRIC ASSOCIATION

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

Madrid, Spain 12-15 March 2016  
[www.epa-congress.org](http://www.epa-congress.org)

TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY

## FINAL PROGRAMME

### EPA ADMINISTRATIVE OFFICE

15, Avenue de la Liberté  
67000 Strasbourg, France  
Tel. + 33 3 8823 9930  
Fax + 33 3 8835 2973  
[hq@europsych.net](mailto:hq@europsych.net)

### EPA BRUSSELS OFFICE

University Foundation  
11 rue d'Egmont  
1000 Brussels, Belgium  
Tel. +32 2 511 02 30



### CONGRESS SECRETARIAT



Kenes International Organisers of  
Congresses S.A.  
Rue François-Versonnex 7  
1207 Geneva, Switzerland  
Tel. + 41 22 908 04 88  
Fax + 41 22 906 91 40  
[epa@kenes.com](mailto:epa@kenes.com)

# TABLE OF CONTENTS

<b>CONGRESS INFORMATION</b>	<b>03</b>
Welcome Address	03
General Information	04
Congress Activities	06
EPA Forum	07
Mobile Application	08
EPA 2016 Scientific Programme Overview	09
Information for Presenters	10
e-Posters	11
Congress Accreditation and Certificate of Attendance	12
European Early Career Psychiatrists' (EECP) Programme	14
About the European Psychiatric Association	15
EPA Prizes and Awards	17
EPA Membership	19
<b>SCIENTIFIC PROGRAMME</b>	<b>21</b>
Saturday, 12 March	21
Sunday, 13 March	27
Monday, 14 March	57
Tuesday, 15 March	85
<b>INDEX OF AUTHORS</b>	<b>105</b>
<b>COMPANY AND EXHIBITION GUIDE</b>	<b>113</b>
Acknowledgements	115
Industry Supported Satellite Symposia	116

# WELCOME ADDRESS

Dear Colleagues,

The **24<sup>th</sup> European Congress of Psychiatry (EPA 2016)**, taking place 12–15 March 2016 in Madrid, Spain, is a major meeting of European psychiatrists dedicated to promoting European psychiatry and to improving mental health around the globe. On behalf of the European Psychiatric Association (EPA), it is our great pleasure to welcome you to this occasion.

Guided by the motto **Towards a Common Language in European Psychiatry**, we have prepared a top-notch scientific programme that will cover the newest achievements in the field covering basic, clinical and translational research, and their application to evidence-based practice in diagnosis, treatment and education.

Through a variety of session types, including Plenary Lectures, EPA Courses and a dedicated European Early Career Psychiatrists Programme, EPA 2016 will meet the needs of all participants, from trainees in psychiatry to the most esteemed experts.

The EPA is committed to helping psychiatrists network, share research and learn from their colleagues and peers across Europe and beyond. Accordingly, we have developed an array of activities at the European Congress of Psychiatry which will allow these valuable connections to continue and flourish.

We welcome you to the enchanting city of Madrid and to EPA 2016.



**Wolfgang Gaebel**  
EPA President




**Miguel Gutiérrez Fraile**  
Local Organising Committee Chair



# GENERAL INFORMATION

## CONGRESS VENUE

Palacio Municipal de Congresos  
 Campo de las Naciones  
 Avda. Capital de España Madrid  
 28042 Madrid – Spain

## LANGUAGE

English is the official language of the Congress.

## REGISTRATION

The Registration Desk is situated on the ground floor of the Congress Center and will operate during the following hours:

Saturday, 12 March	08:00 – 19:30
Sunday, 13 March	07:00 – 18:45
Monday, 14 March	07:30 – 18:45
Tuesday, 15 March	07:30 – 17:00

## EPA BOOTH OPENING HOURS

The EPA Booth is located in the Exhibition Area and will be open at the following times:

Sunday, 13 March – Tuesday, 15 March	09:00 – 17:00
--------------------------------------	---------------

## EXHIBITION OPENING HOURS

Exhibition opening hours are:

Sunday, 13 March	09:00 – 17:00
Monday, 14 March	09:00 – 17:00
Tuesday, 15 March	09:00 – 17:00

## NAME BADGE

Upon registration, you will receive your name badge. You are kindly requested to wear your badge during all Congress sessions and events.

## MOBILE PHONES

Mobile phones must be switched off or muted during all sessions.

## SMOKING POLICY

Smoking is prohibited throughout the Congress venue. Please be considerate of the rules of the venue and your fellow participants.

## LIABILITY AND INSURANCE

The Congress Secretariat and Organisers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised not to leave their personal belongings unattended in session halls and throughout the Congress centre.

## PHOTOGRAPHY AND RECORDING PRIVILEGES

No photographs, video recording or audio recording may be permitted in the scientific sessions at this Congress unless otherwise authorized by the Scientific Programme Committee or the EPA President.

## GUEST ATTENDANCE POLICY

All event activities (including educational sessions, meal functions, exhibition hall, etc.) are exclusively reserved for registered attendees. Non-registered guests (including children, family members, colleagues, etc.) are not allowed in any of the event areas. Badges provided at registration are required for entrance into all functions and will be strictly enforced.

## REFRESHMENTS AND BREAKS

Refreshments will be provided during the coffee breaks. For your convenience cash bars are available in the Exhibition Area during lunch breaks.

## INDUSTRY

In accordance with compliance regulations, Industry supporting the Congress will be acknowledged separately from the Scientific Programme. Industry Information will appear at the back of the book, under the section Company and Exhibition Guide.

## ABSTRACTS

All accepted abstracts are published in an online supplement of the *European Psychiatry* journal published by Elsevier. Abstract viewing is also available at the internet stations in the Exhibition Area. ([epa-abstracts-2016.elsevier.cc](http://epa-abstracts-2016.elsevier.cc))

# CONGRESS ACTIVITIES

## SATURDAY, 12 MARCH

### EPA FORUM A COMMON LANGUAGE IN EUROPEAN PSYCHIATRY: CAN IT BE ACHIEVED?

09:00 – 13:50 | Roma Hall

### OPENING CEREMONY

18:30 – 20:00 | Auditorium A  
Palacio Municipal de Congresos (Congress Venue)

### WELCOME RECEPTION

20:00 | on the Ground Level

### EUROPEAN EARLY CAREER PSYCHIATRISTS' NETWORKING EVENT

21:00 | 3<sup>rd</sup> Floor Foyer

EPA wishes to welcome delegates to EPA and enable them to benefit from the Congress to the fullest extent as well as from a valuable opportunity to meet new colleagues.

Tickets at €15 per person are available from the Registration Desk for all registered participants.

## SUNDAY, 13 MARCH

### EPA EXTRAORDINARY GENERAL ASSEMBLY & ORDINARY GENERAL ASSEMBLY

18:45 | Paris Hall

This event is reserved for members. Please collect your invitation for this event from the EPA booth in the Exhibition Area.

# EPA FORUM

The **2<sup>nd</sup> EPA Forum** "A Common Language in European Psychiatry: Can it be achieved?" will take place from 09:00 – 13:50 on Saturday, 12 March 2016, followed by a light lunch. Please refer to page 23 for the full EPA Forum programme.

Following the success of the first EPA Forum at the European Congress of Psychiatry in 2015 in Vienna, this new event for exchange and awareness is to be featured at each annual EPA Congress. It brings together EPA Council of National Society/Association (NPA) members and EPA Individual members, along with other European NPAs and European organisations, stakeholders and policy makers, to present and discuss matters of European importance in the field of Mental Health and Mental Health Care.

## A Common Language in European Psychiatry: Can it be achieved?



**12 March 2016 9:00-13:50**

Palacio Municipal de Congresos, Madrid

*Preceding the 24<sup>th</sup> European Congress of Psychiatry,  
12-15 March 2016, Madrid*

# MOBILE APPLICATION

Install the EPA 2016 interactive mobile App to your smartphone and portable devices to access all the Congress information you could need during and after the Congress:

- See the overview of sessions, speakers and exhibitors
- Create your own programme for the event, including bookmarking the sessions you wish to attend
- Receive real-time updates

Download the EPA App now to enhance your Congress experience! (available on the App Store or Google Play: **EPA 2016 Madrid**)

## INTERNET STATIONS

Internet stations are located in the Exhibition Area and are available during Exhibition Opening Hours only.

Abstract Viewing is available at the Internet Stations.

Please do be considerate of fellow participants when using these facilities.

## WIFI

Free internet is available to all Congress participants in the Congress Center.

**NETWORK NAME:** **epa-2016**





**PASSWORD:** **epa-2016**

## SOCIAL MEDIA

Please Tweet about the Congress using hashtag **#EPA2016** and username **@Euro\_Psychiatry**.




# SCIENTIFIC PROGRAMME OVERVIEW

The EPA 2016 Scientific Programme is composed of 4 main tracks; each track is composed of a variety of Plenary, State of the Art, Pro & Con Debates, Symposia, and Workshop sessions:

-  **Research Track** – is composed of sessions with a focus on current research trends in psychiatry.
-  **Clinical / Therapeutic Track** – offers participants updated, state-of-the-art, clinical and therapeutic information which is based on research and linked to daily practice.
-  **Educational Track** – provides an update on developments in the field and the opportunity for exchange of ideas between participants and speakers.
-  **European Track** – deals with common issues for psychiatrists across Europe and will therefore be of particular interest for members of the National Psychiatric Associations.

Within each track, some sessions are part of the European Early Career Psychiatrists' Programme (EECPP) which invites recent graduates to participate and which is tailored to the needs of the Early Career Psychiatrist.

The Scientific Programme will also include:

-  **Free Communications Sessions** – There are 8 Free Communications Sessions classified by topics, in which the authors of selected outstanding abstracts will give a talk.
-  **Industry Supported Sessions** – There are 3 Satellite Symposia organised by pharmaceutical companies in consultation with the Scientific Programme Committee. Learn more about the Satellite Symposia on pages 116-117.
-  **E-Posters** – There are e-Poster viewings classified by topics, in which outstanding posters will be presented electronically. There are also 15 daily e-Poster Walk Sessions that take place during the lunch breaks.

 **Section Symposia, Workshops and EPA Courses**

 **Session requiring pre-registration**

 **2016 Section Symposia Award Winner**

 **European Early Career Psychiatrists' Programme**

# INFORMATION FOR PRESENTERS

Please check the online interactive Programme in case of last minute scheduling changes.

## SPEAKERS' READY ROOM

Saturday, 12 March	08:00 – 19:30	Monday, 14 March	07:30 – 18:45
Sunday, 13 March	07:30 – 18:45	Tuesday, 15 March	07:30 – 17:00

## ORAL PRESENTATIONS

### Data presentation

If using a PowerPoint (or any other computer) presentation, please note you need to bring it on a CD, a DVD or on a USB key and load it on one of the Congress' computers in the Speakers' Ready Room, at least 1 hour before the start of the session. Please note that the Congress computers in the session halls are being supplied with Office 2013.

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a coffee or lunch break prior to your session, at least 30 minutes before the start of the session – **even after checking it in the Speakers' Ready Room.**

Alternatively you may supply your own laptop computer. In such a case please confirm that it has a VGA socket for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

### Important note for Macintosh users

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers' Ready Room:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).
2. Insert pictures as JPG files (and not TIF, PNG or PICT – these images will not be visible on a PowerPoint based PC).
3. Use a common movie format, such as AVI and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC).

Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it with a VGA adaptor for external signal and come to check it first in the Speakers' Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

**Please note: in compliance with EACCME requirements all speakers are requested to include a slide disclosing conflicts of interest at the beginning of their presentation.**

# e-POSTERS

Participants and members will be granted access to an advanced e-Poster platform, which provides user-friendly access all posters online, during and after the Congress. Users will be able to browse by e-Poster sections and features educational tools such as searching for specific content, being able to comment on posters and ask questions to the authors. When permitted by the authors, posters will be available for download in PDF format. e-Poster viewing stations will be available at the e-Poster Area on Floor 3.

If you have not submitted your e-Poster prior to the Congress via the online system, please bring it on a USB key to the e-Poster Helpdesk at the Congress venue.

## e-POSTER WALKS

There are 15 e-Poster Walks scheduled on Sunday and Monday and on Tuesday there are 14 e-Poster Walks. Each e-Poster walk station will feature between 18 and 20 e-Posters. All e-Poster walks will take place in the e-Poster Area during the lunch break.

# CONGRESS ACCREDITATION AND CERTIFICATE OF ATTENDANCE

## EUROPEAN ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (UEMS/EACCME)

An application has been made to the UEMS-EACCME® for CME accreditation of this event. The EACCME is an institution of the European Union of Medical Specialists (UEMS): [www.uems.net](http://www.uems.net)

## AMERICAN MEDICAL ASSOCIATION (AMA)

Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of *AMA PRA Category 1 Credits™*. Information on the process to convert EACCME credit to AMA credit can be found at [www.ama-assn.org/go/internationalcme](http://www.ama-assn.org/go/internationalcme).

## ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. For more information, visit: [www.royalcollege.ca](http://www.royalcollege.ca).

## CREDIT BREAKDOWN

Each participant should claim only those hours of credit that he/she actually spent in the educational activity.

DAY	MAXIMUM CREDITS
Saturday, March 12 2016	3
Sunday, March 13 2016	6
Monday, March 14 2016	6
Tuesday, March 15 2016	6
<b>TOTAL CREDITS</b>	<b>21</b>

## TO RECEIVE YOUR CME/CPD CERTIFICATE

The CME/CPD certificate will be available after completing the online evaluation and credit claiming procedure. The process takes about 5 minutes. We thank you for your feedback as it is an important part of CME/CPD accreditation and helps improve future educational offerings.

1. Access the online system via any of the following
  - The claiming link will be provided after the Congress.
  - Visit the CME/CPD Accreditation page on the event website
  - Follow the link in the email sent at the end of the event
2. Complete the anonymous online evaluation
3. Complete the credit claim form and submit
4. The CME/CPD certificate will be available for download; fill-in and retain for your personal records

## DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with CME/CPD accreditation criteria and standards for commercial support to ensure balance, independence, objectivity, and scientific rigor, those in control of the educational content must disclose potential or actual conflicts of interest. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants will be asked on the evaluation to assess the objectivity and independence of the event.

Disclosure information is available on the Congress website.

## EPA COURSES, ACCREDITATION AND CERTIFICATE

EPA Courses will be held throughout the Congress. Pre-registration for Courses is required. EPA members can register for 2 courses for the price of 1. Please contact the registration desk for additional information regarding availability of courses and registration. Participants are requested to present their Course ticket at the entrance of the appropriate hall.

## ACCREDITATION

The EPA Courses are accredited within the accreditation of the 24<sup>th</sup> European Congress of Psychiatry EPA 2016. EPA Courses are designated for a maximum of, or up to, 3 European CME credits (ECMEC) per course. These are to be claimed within the total number of CME credits claimed for EPA 2016, while respecting the maximum number of credits per day.

## CERTIFICATE OF ATTENDANCE AT COURSES

Certificate of Attendance for the Courses will be available after the Congress. A survey link will be sent to course participants. After completing the survey, you may claim your certificate electronically.

# EUROPEAN EARLY CAREER PSYCHIATRISTS' PROGRAMME

## EECP

The European Early Career Psychiatrists' (EECP) Networking Area is situated in the Montevideo Hall on Floor 2 and is dedicated to Early Career Psychiatrists and Trainees, offering the opportunity for networking.

The area will be open at the following times:

Sunday, 13 March	08:00 – 18:30
Monday, 14 March	08:00 – 18:30
Tuesday, 15 March	08:00 – 17:00

All EECP sessions take place in the La Paz Hall.

### EECP PROGRAMME

SATURDAY, 12 MARCH 2016 | 21:00 | 3<sup>RD</sup> FLOOR FOYER

European Early Career Psychiatrists' Networking Event

#### SUNDAY, 13 MARCH 2016

10:00 – 11:30	Conversations – The Political and Social Mission of Psychiatry
15:00 – 16:30	Court Debates – Mindful or Mindless: Mindfulness is More Than Just a Hype?

#### MONDAY, 14 MARCH 2016

08:00 – 09:30	Court Debates – Should Gender Identity Disorder Should be Considered a Mental Illness?
10:00 – 11:30	EFPT/ ECPC-EPA Symposium – Identity and Competency: How to Train the Modern Day Psychiatrist
10:00 – 11:30	Early Career Psychiatrists Workshop – Getting Started: The First Steps in Psychiatric Consultation
15:00 – 16:30	Training Workshop: Using Ethics in Daily Psychiatry
17:00 – 18:30	Symposia – Services Users and Carers are Experts in Mental Health

#### TUESDAY, 15 MARCH 2016

08:00 – 09:30	Training Workshop – Dissociative Symptoms, How to Recognise and Treat them
10:00 – 11:30	Conversations – Tackling Suicide Where There are too Few Psychiatrists
13:15 – 14:45	EFPT/ ECPC-EPA Symposium – Research by Trainees and Early Career Psychiatrists

# ABOUT THE EUROPEAN PSYCHIATRIC ASSOCIATION

The European Psychiatric Association (EPA) was founded in 1983. With active individual members in as many as 88 countries and 39 National Psychiatric Associations who joined as members in 2012 and who represent over 78,000 European Psychiatrists, EPA is the main association representing psychiatry in Europe. Its mission is to improve psychiatry and mental health care in Europe. EPA members include leading experts in numerous fields, covered by 21 scientific Sections. EPA's activities address the interests of psychiatrists in academia, research and practice throughout all stages of career development. Together, EPA members contribute to the life of the association and to the development of Psychiatry in Europe. Each member has the possibility to actively contribute to ongoing projects and play a key role in shaping the future of the Association and its policy.

One of the important tasks for a European association is to maintain strong links with other European and international institutions and associations such as the Council of Europe, the World Health Organization (WHO), the European Union (EU), the European Union of Medical Specialists (UEMS), the European College of Neuropsychopharmacology (ECNP), the World Psychiatric Association (WPA), the European Brain Council (EBC), the European Federation of Psychiatric Trainees (EFPT), the European Conference on Schizophrenia Research (ECSR) and several patient and relatives organisations, such as the European Federation of Associations of Families of People with Mental Illness (EUFAMI) and the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe).

## MISSION

To improve psychiatry and mental health care in Europe.

## ACTIVITIES

EPA accomplishes its mission through the following activities:

- Annual European Congress of Psychiatry
- *European Psychiatry* Journal, published in 8 issues per year, plus supplements
- EPA Courses, Summer School, Faculty Workshop and other forms of training under the umbrella of the EPA Academia for Excellence in European Psychiatry
- European Early Career Psychiatrists Programme and other projects aiming to give young professionals a voice in the evolution of training, research and practice standards to enable them to influence their own future and career progress
- A range of grants and prizes in psychiatric research
- 21 Sections, which collect, examine and disseminate information about their respective disciplines
- Cooperation with National Psychiatric Associations through EPA membership

- Practical guidance and position statements on topics of interest to the mental health community and beyond
- Initiatives on improving ethical standards of psychiatric care and practice
- Collaborative activities in partnership with international organisations working in the field of psychiatry and mental health care

For more information on EPA, visit [www.europsy.net](http://www.europsy.net).

Please consult the EPA 2016 Mobile Application for further information on:

- EPA Committees
- EPA Sections
- EPA National Society/Association Members
- EPA Administrative Meetings and EPA Section Meetings

## PRIZES AND AWARDS

One of EPA's missions is to accompany Early Career Psychiatrists in their professional development. The Association proposes a panel of grants and prizes. The European Psychiatric Association is delighted to award the following prizes at the 24<sup>th</sup> European Congress of Psychiatry. The Award Ceremony will take place during the Opening Ceremony on Saturday, 12 March at 18:30 in Auditorium A.

### 2016 RESEARCH PRIZE WINNERS

Four Research Prizes of €2,500 each to Early Career Psychiatrists working in Europe, who published the best scientific papers in 2015, have been awarded to:

**CATEGORY 1: Clinical Psychopathology and Refinement of Psychiatric Diagnostic Categories**  
Rashmi Patel, *United Kingdom*

**CATEGORY 2: Biological Correlates and Treatments of Mental Disorders**  
Adrian Georg Fischer, *Germany*

**CATEGORY 3: Psychiatric Epidemiology, Social Psychiatry and Psychotherapeutic Interventions in Mental Disorders**  
Nicolas Hoertel, *France*

**CATEGORY 4: Child and Adolescent Psychiatry**  
Agnieszka Butwicka, *Sweden/Poland*

### 2016 SCHOLARSHIP PROGRAMME FOR EARLY CAREER PSYCHIATRISTS & TRAINEES

The EPA Scholarship Programme provides a special grant including free Congress entrance to the European Congress of Psychiatry, travel expenses, hotel accommodation, complimentary registration for one EPA Course, invitation to Early Career Psychiatrists Luncheon and free EPA membership in 2016. The scholarship is available for early career psychiatrists who are either trainees or within 5 years of completion of specialist training in psychiatry and who are working in countries that form part of the World Health Organisation Europe region.

The 2016 Scholarship Programme winners are:

**Livia de Picker**, *Belgium*  
**Howard Ryland**, *United Kingdom*  
**Iria Grande**, *Spain*  
**Ozge Kilic**, *Turkey*  
**Miloš Milutinovic**, *Rep. of Macedonia*



## EPA SECTION SYMPOSIA AWARDS

The EPA Section Symposia Awards were created to promote a high quality programme proposed by the Sections for the 24<sup>th</sup> European Congress of Psychiatry and to promote cooperation with EPA Sections and EPA National Psychiatric Society/Association members.

The accepted Sections Symposia were ranked on the following criteria:

- Quality and relevance (scientific, clinical, educational) of the symposium
- Cooperation with another Section
- Cooperation with National Society Sections

The 5 Section Symposia Awards for 2016 are:

- Affective and Psychotic Psychopathology During Adolescence and Early Adulthood:  
The Dynamic Developmental Interplay between Genes, Structures and Functions  
Sections: Neuroimaging; Child and Adolescent Psychiatry  
**Sunday, 13 March | Londres Hall | 10:00 – 11:30**
- Treatment of People with Dual Diagnosis  
Section: Psychopharmacology  
**Sunday, 13 March | Roma Hall | 10:00 – 12:30**
- Hallucinations and Delusions in Schizophrenia: from Phenomenology to Neurobiology  
Sections: Schizophrenia; Psychopathology  
**Sunday, 13 March | Londres Hall | 17:00 – 18:30**
- Phenomenology of Anxiety  
Sections: Philosophy and Psychiatry; Psychopathology  
**Monday, 14 March | Amsterdam Hall | 17:00 – 18:30**
- Racism and Discrimination in Mental Health Care of Immigrants  
Section: Cultural Psychiatry  
**Tuesday, 15 March | Madrid Hall | 10:00 – 11:30**



EUROPEAN PSYCHIATRIC ASSOCIATION

## EPA MEMBERSHIP

**Join EPA for only €100 annual fee**

To become an individual member of EPA,  
you are invited to complete an application form  
on the EPA website: [www.europsy.net/join-us](http://www.europsy.net/join-us).

### THE ADVANTAGES OF EPA MEMBERSHIP:

#### LEARN

Keep informed about the latest scientific research and treatments

#### NETWORK

Integrate the network of European practitioners and researchers  
in Psychiatry

#### CONTRIBUTE

Get involved in the association and take an active part in the  
development of Psychiatry in Europe

#### ADVANCE

Accelerate your career and professional development

#### INFLUENCE

Have a voice and a role in shaping the future of the profession

#### MEMBER BENEFITS:

- An electronic subscription to *European Psychiatry* journal
- Discounted registration fees for the annual European Congress of Psychiatry
- Preferential prices for EPA Courses
- An invitation to EPA General Assembly and right to vote (depending on membership category)
- Access to the EPA Extranet and member directory
- An invitation to join 21 scientific Sections
- Visibility on European Psychiatric Network
- Subscription to EPA Minds Online newsletters

**Find out more at: [www.europsy.net](http://www.europsy.net)**

This image shows a single page of white paper with horizontal blue lines, resembling notebook paper. The lines are evenly spaced and run across the width of the page. There is no handwriting or other markings on the paper.

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

**Madrid, Spain 12-15 March 2016**  
**[www.epa-congress.org](http://www.epa-congress.org)**

## TOWARDS A COMMON LANGUAGE IN EUROPEAN PSYCHIATRY

# SCIENTIFIC PROGRAMME

## SATURDAY, 12 MARCH

## 2016



EUROPEAN PSYCHIATRIC  
ASSOCIATION

# EPA 2016 AT YOUR FINGERTIPS

Search "EPA 2016" and Download the  
App for the Full Congress Experience



<http://lp.epa-congress.org/app2016/>

## SCIENTIFIC PROGRAMME SATURDAY, 12 MARCH 2016

9:00 – 13:50

Roma Hall

### EPA Forum: A Common Language in European Psychiatry: Can it be Achieved?

#### 9:00 Welcome and Introduction

W. Gaebel (*EPA*)

#### Video message from the European Commission

J.F. Ryan (*EC Public Health Directorate*)

#### European Psychiatry: What are the Concepts?

Chair: W. Gaebel

#### 9:25 Why a European Psychiatry? Balancing Unity and Diversity?

M. Maj (*University of Naples*)

#### 9:45 Human Rights and Mental Health Care – Can we Find a Common Ground?

D. Pūras (*UN Special Rapporteur on Health*)

#### 10:05 Discussion

#### 10:15 Coffee Break

#### European Psychiatric Workforce: Generalists or Specialists?

Chair: S. Galderisi

#### 10:30 European Psychiatrists: What Unifies us – What is our Role?

W. Gaebel (*EPA*)

#### 10:50 National Psychiatric Associations and EPA: What are Core Principles in Education?

M.M. Carrasco (*EPA*)

#### 11:10 European Research: Where Should we Set the Focus?

J.M. Haro (*ROAMER*)

#### 11:30 Discussion

11:40 **Coffee Break**

**European Mental Health Service: The Value of Treatment and Care**

Chair: D. Wasserman

11:55 **Outcomes of Promotion, Prevention, Treatment and Care**

M. Muijen (*WHO – Europe*)

12:15 **Economic Aspects in European Mental Health Services**

M. Knapp (*London School of Economics*)

12:25 **Patients' and Relatives' View on European Psychiatry**

B. Johnson (*EUFAMI*)


Y. Cohen (*GAMIAN*)

12:45 **General Discussion Moderated by Wolfgang Gaebel**

13:40 **Concluding Remarks**

W. Gaebel (*EPA*)


13:50 **EPA Forum Lunch**

**14:45 – 18:15**  **Paris Hall**

EPA Course:

**Writing, Publishing and Reviewing a Scientific Paper**

C. Lauber (*Switzerland*)

**14:45 – 18:15**  **Berlin Hall**


EPA Course:

**How to Manage Delirium in the General Hospital**

A. Diefenbacher (*Germany*)

A. Barbosa (*Portugal*)



D. Georgescu (*Switzerland*)

**14:45 – 18:15**  **Londres Hall**

EPA Course:

**Leadership Skills in Psychiatry**

D. Bhugra (*United Kingdom*)

**14:45 – 18:15**   **Amsterdam Hall**

EPA Course:

**Risk Assessment and Risk Management in General Psychiatry**

K. Goethals (*Belgium*)

N. Nedopil (*Germany*)



**14:45 – 18:15**   **Montevideo Hall**

EPA Course:

**Cultural Competence Training – According to the EPA Guidance on Cultural Competence Training**

M. Schouler-Ocak (*Germany*)

I.T. Graef-Callies (*Germany*)

**14:45 – 18:15**   **Madrid Hall**

EPA Course:

**Attention – Deficit / Hyperactivity Disorder (ADHD) in Adults: Nosology, Diagnostic Process and Treatment**

E. Sobanski (*Germany*)

P. Asherson (*United Kingdom*)

J. Ramos-Quiroga (*Spain*)

**16:15 – 16:45**

**Coffee Break**



14:45 – 18:15



Sala de Prensa Hall 2

EPA Course:

**Diagnosis and Management of Mental Illness in People with Intellectual Disability – What is Different?**

B. Perera (*United Kingdom*)

K. Courtenay (*United Kingdom*)

14:45 – 18:15



La Habana Hall

EPA Course:

**How to Manage and Treat Patients Suffering from Mental Disorders? From Evidence-Based to Human-Based Medicine**

M. Musalek (*Austria*)

14:45 – 18:15



La Paz Hall

EPA Course:

**Understanding Psychosis: A Psychopathological Guide for Clinical Examination**

A. Raballo (*Norway*)

P. Handest (*Denmark*)

F. Larøi (*Belgium*)

18:15 – 18:30

Short Break

18:30 – 21:00

Auditorium A

Opening Ceremony followed by a Welcome Reception



EUROPEAN PSYCHIATRIC ASSOCIATION

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

Madrid, Spain 12-15 March 2016

[www.epa-congress.org](http://www.epa-congress.org)

TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY

## SCIENTIFIC PROGRAMME SUNDAY, 13 MARCH 2016

# IACAPAP 2016

Fighting Stigma: Promoting Resiliency and Positive Mental Health



The 22<sup>nd</sup> International Association for Child and Adolescent Psychiatry and Allied Professions World Congress (IACAPAP)




36<sup>th</sup> Annual Conference for the Canadian Academy of Child and Adolescent Psychiatry (CACAP)

September 18-22, 2016 | Calgary TELUS Convention Centre | Calgary, Alberta, Canada

*"As far as we can discern, the sole purpose of human existence is to kindle a light in the darkness of mere being"*

*- C. G. Jung*



Tourism Calgary

## REGISTER NOW

Register by Monday, May 16, 2016 to save \$100!



Tourism Calgary

- ◆ Scientific Program featuring over 200 sessions, institutes and workshops
- ◆ 800+ Posters presented over four days
- ◆ Exhibit Hall
- ◆ Opening Ceremony, Welcome Reception, Congress Dinner

[www.iacapap2016.org](http://www.iacapap2016.org) | #IACAPAP2016 | [@IACAPAP2016](https://twitter.com/IACAPAP2016) | [f](https://www.facebook.com/IACAPAP) IACAPAP

EPA 2016  
FINAL PROGRAMME

## SCIENTIFIC PROGRAMME SUNDAY, 13 MARCH 2016

8:00 – 9:30

S

Auditorium A

Symposium:

**Suicidology in the 21<sup>st</sup> Century**

Chairs: P. Courtet (*France*)

V. Carli (*Sweden*)

8:00 **A Neurosciences Based – Semiology of Suicidal Behaviour**

P. Courtet (*France*)

8:20 **May Volta Help Clinicians in Predicting Suicide?**

M. Sarchiapone (*Italy*)

8:40 **Information and Communication Technologies for the Follow up of Patients**

E. Baca-Garcia (*Spain*)

9:00 **Follow up and Chain of Care in the Prevention of Suicide Recurrence**

P.A. Sáiz Martínez (*Spain*)

9:20 **Discussion**

**8:00 – 9:30** **S** **Madrid Hall**

## Symposium:

**Addictions and Addictive Behaviours: Psychopathological, Philosophical and Ethical Reflections**

 Chairs: P. Varandas (*Portugal*)  
 M. Musalek (*Austria*)

- 8:00 **The Synthetic Psychosis Substances Induced: A Clinical Case Study**  
 G. DiPetta (*Italy*)
- 8:20 **The Myth of Weak-Will**  
 M. Musalek (*Austria*)
- 8:40 **Addiction in the Realm of Possible**  
 G. Bernegger (*Switzerland*)
- 9:00 **The Ethical Principles on Treatment Organization**  
 C. Ramalheira (*Portugal*)
- 9:20 **Discussion**

**8:00 – 9:30** **S** **Roma Hall**

## Symposium:

**Is Schizophrenia a Disorder of Brain Connectivity?**

 Chairs: S. Galderisi (*Italy*)  
 W. Gaebel (*Germany*)

- 8:00 **Motor Symptoms and Altered Connectivity in Schizophrenia**  
 S. Walther (*Switzerland*)
- 8:20 **Disintegration of Sensorimotor Brain Networks in Schizophrenia**  
 T. Kaufmann (*Norway*)
- 8:40 **Brain Dysconnectivity and Vulnerability to Psychosis**  
 S. Borgwardt (*Switzerland*)
- 9:00 **Fronto-Thalamic Dysconnectivity and Cognitive Control in Schizophrenia**  
 G. Wagner (*Germany*)
- 9:20 **Discussion**

**8:00 – 9:30** **Londres Hall**

## Symposium:

**Engaging Students with Psychiatry: Why, How, and Where are we Now**

 Chairs: C. Wilson-Jones (*United Kingdom*)  
 D. Bhugra (*United Kingdom*)

- 8:00 **Introducing PEEP: The Psychiatry Early Experience Programme**  
 H. Qureshi (*United Kingdom*)
- 8:20 **Medical Students Choice of Psychiatry – An International Survey**  
 D. Bhugra (*United Kingdom*)
- 8:40 **Papageno Program: When Learners Collaborate for a Safer Coverage of Suicide**  
 C. Notredame (*France*)
- 9:00 **Youth leadership in Mental Health: Views from EFPT and IFMSA**  
 M. Pinto da Costa (*Portugal*)
- 9:20 **Discussion**

**8:00 – 9:30** **Paris Hall**

## Symposium:

**Improving Clinical Outcomes Through Technology: An Innovative Approach Proposal**

 Chairs: B. Reneses (*Spain*)  
 P. Diego (*Spain*)

- 8:00 **Value-Based Healthcare Delivery in the Digital Era**  
 J. Mayol (*Spain*)
- 8:20 **Smartphone Based Treatment in Bipolar Disorder**  
 M. Faurholt-Jepsen (*Denmark*)
- 8:40 **A Spanish Computerized Guideline for Depression in Primary Care**  
 P. Diego (*Spain*)
- 9:00 **Big Data Analysis for Improved Mental Healthcare: A Population Based Perspective**  
 K. Suzuki (*Japan*)
- 9:20 **Discussion**

**8:00 – 9:30** **Amsterdam Hall**

## Workshop:

**Age of Onset of Mental Disorders: Etiopathogenetic and Treatment Implications**

 Chairs: N. Sartorius (*Switzerland*)  
 R. Murray (*United Kingdom*)

- 8:00 **Familiality, Gender and Cannabis use Determine Age of Onset in Schizophrenia**  
 R. Murray (*United Kingdom*)
- 8:10 **Age of Onset of Bipolar Disorders: A Systematic Review and Meta-Analysis**  
 G. de Girolamo (*Italy*)
- 8:20 **The Age of Onset of Anxiety Disorders in Samples from the General Population: A Meta-Analysis**  
 J. de Lijster (*The Netherlands*)
- 8:30 **Anticipation of Age at Onset in Anorexia Nervosa**  
 A. Favaro (*Italy*)
- 8:40 **Discussion**

**8:00 – 11:30**   **Berlin Hall**

## EPA Course:

**Depression in the Elderly**

 G. Stoppe (*Switzerland*)

**8:00 – 9:30**  **Bratislava Hall**

## Symposium:

**Co-Occurring Psychiatric and Substance Use Disorders: Impact on Illness Course and Recovery**

 Chairs: G. Dom (*Belgium*)  
 A. Heinz (*Germany*)

- 8:00 **Autism and Substance Use Co-Morbidity; Screening, Identification and Treatment**  
 P.J.M. van Wijngaarden-Cremers (*The Netherlands*)
- 8:20 **Alcohol and Aggression**  
 A. Heinz (*Germany*)
- 8:40 **Are Attention Deficit/Hyperactivity Disorder Symptoms Associated with a more Severe Course of Substance use? A Longitudinal Study with Young Swiss Men**  
 F. Moggi (*Switzerland*)
- 9:00 **Multi-Morbidity; Psychosis Early Childhood Adversity and Substance Use within Home-Less People**  
 M. Krausz (*Canada*)
- 9:20 **Discussion**

---

**8:00 – 9:30** **La Habana Hall**


---

Oral Communications:

**Addictive Behaviours, Anxiety Disorders and Somatoform Disorders, Child and Adolescent Psychiatry, Comorbidity/Dual Pathologies, Eating Disorders, Obsessive-Compulsive Disorder**

- 8:00 **"Dual Disorder with Drugs": Comparison of Two French Databases**  
 A. Batisse (*France*)
- 8:07 **25I-NBOMe: The Legal LSD**  
 I. Ezquiaga (*Spain*)
- 8:14 **Alcohol, Caffeine and Tobacco Use during Pregnancy and Associated Risk Factors in a Population-Based Study**  
 R. Navinés (*Spain*)
- 8:21 **Maternal Smoking During Pregnancy and Offspring's Psychiatric Morbidity in Early Adulthood. Findings from the Finnish Family Competence Birth Cohort Study**  
 S. Niemelä (*Finland*)
- 8:28 **Searching for New Markers of Panic Disorder – the Examination of Stem Cells Mobilization and Levels of Factors Involved in their Trafficking**  
 J. Kucharska-Mazur (*Poland*)
- 8:35 **Separating Efficacy and Sedative Effects of Guanfacine Extended Release in Children and Adolescents with ADHD from Four Randomized, Controlled, Phase 3 Clinical Trials**  
 M. Huss (*Germany*)
- 8:42 **Suicidality and Psychiatric Comorbidities among Adults with Childhood Identified ADHD: Gender Differences – a Population-Based Longitudinal Study**  
 K. Yoshimasu (*Japan*)
- 8:49 **Role of Metabolic, Atherogenetic and Psychological Factors in Patients with Colorectal Adenomas: Preliminary Results of the Psycho- Neuro- Endocrino- Immunology Modena (PNEI-MO) Research Group**  
 G. Mattei (*Italy*)
- 8:56 **Clinical Features in Insulin-Treated Diabetes with Comorbid Diabulimia, Disordered Eating Behaviors and Eating Disorders**  
 V. Deiana (*Italy*)

- 9:03 **Gender and Age Differences in Eating and Drinking Risk Behaviors in Italian High School Students**  
 V. Deiana (*Italy*)
- 9:10 **The Prevalence and Correlates of Haematological Abnormalities in Adult Inpatients with Anorexia Nervosa**  
 C. Hopkins (*United Kingdom*)
- 9:17 **Actions Speak Louder than Words: Enhanced Action Tendencies in Obsessive-Compulsive Disorder: An ERP Study**  
 A. Dayan Riva (*Israel*)

---

**8:00 – 9:30** **La Paz Hall**


---

Symposium:

**Psychosocial Rehabilitation and Mental Health**

- Chairs: W. Rössler (*Switzerland*)  
 R. Drake (*USA*)
- 8:00 **Recovery Orientation of Workplace Rehabilitation**  
 R. Drake (*USA*)
- 8:20 **Quality Assessment of Mental Health Rehabilitation Services**  
 H. Killaspy (*United Kingdom*)
- 8:40 **Evidence-Based Psychosocial Measures in Rehabilitation**  
 T. Becker (*Germany*)
- 9:00 **Families and their Roles in the Rehabilitation Process**  
 B. Johnson (*Belgium*)
- 9:20 **Discussion**

---

**9:30 – 10:00**


---

Coffee Break, e-Poster Viewing &amp; Visit the Exhibition

**10:00 – 11:30** **Auditorium A**

Debate:

**Suicide Risk can be Predicted**

 Chair: T. Kurimay (*Hungary*)

**Pro**

 D. Wasserman (*Sweden*)

**Con**

 G. Zalsman (*Israel*)

**10:00 – 11:30** **Madrid Hall**

Symposium:

**Choosing Wisely – Prioritization in Mental Health Care?**

 Chairs: W. Gaebel (*Germany*)

 S. Bailey (*United Kingdom*)

- 10:00 **Prioritization in Medicine – A Special Role for Mental Healthcare?**  
T. Meyer (*Germany*)
- 10:20 **Choosing Wisely in Germany – Adapting an International Initiative to a National Healthcare Agenda**  
D. Klemperer (*Germany*)
- 10:40 **Choosing Wisely in Youth and Adolescent Psychiatry**  
S. Bailey (*United Kingdom*)
- 11:00 **Choosing Wisely – The Viewpoint and Experiences of the American Psychiatric Association**  
J. McIntyre (*USA*)
- 11:20 **Discussion**

**10:00 – 11:30** **Roma Hall**


Symposium:

**Treatment of People with Dual Diagnosis**

 Chairs: I. Bitter (*Hungary*)

 J. Bobes (*Spain*)

- 10:00 **Treatment Adherence of Patients with Dual Disorders**  
J. Bobes (*Spain*)
- 10:20 **Treating Schizophrenia and Comorbid Substance-Related Disorders**  
S. Galderisi (*Italy*)
- 10:40 **Treating Adult ADHD and Comorbid Substance-Related Disorders**  
J. Ramos-Quiroga (*Spain*)
- 11:00 **Treating Depression and Comorbid Substance-Related Disorders**  
S. Kasper (*Austria*)
- 11:20 **Discussion**

**10:00 – 11:30** **Londres Hall**

## Symposium:

**Affective and Psychotic Psychopathology During Adolescence and Early Adulthood: The Dynamic Developmental Interplay Between Genes, Structures and Functions**

 Chairs: P. Brambilla (*Italy*)  
 R. Brunner (*Germany*)

- 10:00 **Neurodevelopmental Trajectories and Psychopathology in Adolescents and Adults Who were Born very Preterm**  
 C. Nosarti (*United Kingdom*)
- 10:20 **The Impact of Personality and Family Relationships on Brain Development during Adolescence**  
 P. Brambilla (*Italy*)
- 10:40 **Grin2b Mediates Susceptibility to Affective Problems in Children and Adolescents**  
 M. Nobile (*Italy*)
- 11:00 **Corollary Discharge, Auditory Hallucinations and Schizophrenia – A Structural Network Analysis**  
 R. Henze (*Germany*)
- 11:20 **Discussion**

**10:00 – 11:30** **Paris Hall**

## Symposium:

**E-Mental Health: Updates on Recent Achievements and Pitfalls**

 Chairs: D. Hilty (*USA*)  
 D. Mucic (*Denmark*)

- 10:00 **E-Mental Health and Models of Care: The Evidence Base and Feasibility of Picking One vs. Another?**  
 D. Hilty (*USA*)
- 10:20 **Internet Use and Abuse Among an Italian Sample of University Students**  
 A. Fiorillo (*Italy*)
- 10:40 **Treatment of Schizophrenia Using Tablet and Smartphone Based Applications (Polish Study)**  
 K. Krzysztof (*Poland*)

- 11:00 **After All, Is E-Mental Health Capable of Making a Paradigm Shift?**  
 M. Krausz (*Canada*)

- 11:20 **Discussion**

**10:00 – 11:30** **Amsterdam Hall**

## Workshop:

**The Impact of Societal Forces on the Mental Health of LGBT Populations Across Cultures**

 Chairs: R. Montoro (*Canada*)  
 T. Hall (*USA*)

- 10:00 **Cultural Variations in LGBT Issues**  
 D. Bhugra (*United Kingdom*)
- 10:10 **LGBT Adolescents in America: Depression, Discrimination and Suicide**  
 A. Ahuja (*USA*)
- 10:20 **The Association of Bullying with Suicide Ideation and Attempt among Adolescents with Different Dimensions of Sexual Orientation**  
 R. Montoro (*Canada*)
- 10:30 **HIV Pre-Exposure Prophylaxis (PrEP) and Treatment as Prevention (TasP): What Mental Health Providers Should Know**  
 T. Hall (*USA*)
- 10:40 **Discussion**

**10:00 – 11:30 La Habana Hall**

Oral Communications:

**Bipolar Disorders, Depression, Pain and Treatment Options**

 Chair: P. Michel Llorca (*France*)

- 10:00 **Multimorbidity in Affective Disorders: Impact on Length of Stay**  
 F. Cealicu Toma (*Canada*)
- 10:06 **Trends of Hospitalization for Bipolar I in USA: A Nationwide Analysis**  
 Z. Mansuri (*USA*)
- 10:12 **The Impact of Climate on Risk of Mania**  
 C.R. Medici (*Denmark*)
- 10:18 **Delays to Diagnosis and Treatment in Patients Presenting to Mental Health Services with Bipolar Disorder**  
 R. Patel (*United Kingdom*)
- 10:24 **Trends of Hospitalization for Major Bipolar II in USA: A Nationwide Analysis**  
 M. Rathod (*USA*)
- 10:30 **Analysis of Genetic Polymorphisms, Adverse Drug Reactions and Targeted Treatment**  
 E. Stella (*Italy*)
- 10:36 **Trends of Hospitalization for Major Bipolar Unspecified in USA: A Nationwide Analysis**  
 A. Sutaria (*USA*)
- 10:42 **Trends of Hospitalization for Major Bipolar I (Most Recent Episode-Manic) in USA: A Nationwide Analysis**  
 A. Sutaria (*USA*)
- 10:48 **Epigenetic Signature of Glucocorticoid Receptor Is Associated with the Familial Component of Depression: A Twin-Based Study**  
 L. Fañanás (*Spain*)
- 10:54 **Pilot Project: Sound Pillow Treatment to Improve Sleep Quality for Patients with Depression or Bipolar Diagnosis with Sleeping Problems**  
 H. Lund (*Denmark*)
- 11:00 **Sex Differences in Depressive Symptomatology in Patients with Chronic Hepatitis C during Pegylated Interferon Alpha Therapy: A 72-Week Prospective Study**  
 Z. Pavlovic (*Serbia*)

**11:06 Depression as an Interdisciplinary Problem**

 A. Vasileva (*Russia*)

**11:12 The Net Suppression Effect of Pain Catastrophic Cognition on Anxiety Sensitivity**

 W. Wong (*Hong Kong, China*)

**10:00 – 11:30 EEC La Paz Hall**

Early Career Psychiatrists:

**Conversations – The Political and Social Mission of Psychiatry**

 Chairs: O. Kazakova (*Belarus*)

 D. Giacco (*United Kingdom*)

**The Political and Social Mission of Psychiatry**

 S. Priebe (*United Kingdom*)

**11:30 – 11:45**
**Short Break**
**11:45 – 12:30 Auditorium A**

Plenary:

**The Evidence Base of Mental Health Promotion and Illness Prevention**

 Chair: W. Gaebel (*Germany*)

**11:45 The Evidence Base of Mental Health Promotion and Illness Prevention**

 K. Wahlbeck (*Finland*)

**12:30 – 13:15**
**Break, e-Poster Viewing, e-Poster Walks & Exhibition**

---

**13:15 – 14:45** **Madrid Hall**


---

**Satellite Symposium 1 – Not Included in the Main Event CME/CPD**


---

**13:15 – 14:45** **Roma Hall**


---

**Satellite Symposium 2 – Not Included in the Main Event CME/CPD**


---

**14:45 – 15:00**


---

**Short Break**


---

**15:00 – 15:45** **Auditorium A**


---

State-of-the-Art:

**Psychosocial Intervention in Schizophrenia**

 Chair: S. Galderisi (*Italy*)

15:00 **Psychosocial Intervention in Schizophrenia**  
 T. Wykes (*United Kingdom*)

---

**15:45 – 16:30** **Auditorium A**


---

State-of-the-Art:

**Differential Diagnosis of Sexual Dysfunction: What can be Done?**

 Chair: J.N. Beezhold (*United Kingdom*)

15:45 **Differential Diagnosis of Sexual Dysfunction: What can be done?**  
 M. Waldinger (*The Netherlands*)

---

**15:00 – 16:30** **Madrid Hall**


---

Symposium:

**Towards Personalized Pharmacotherapy for Suicide Prevention Across the Lifespan**

 Chairs: J.J. Mann (*USA*)

 E. Isometsa (*Finland*)

15:00 **Using Genomics to Predict Antidepressant Response in Suicidal Depressed Children**  
 A. Apter (*Israel*)

15:20 **Age and Pharmacotherapy of Suicidal Depressed Bipolar Patients**  
 M.A. Oquendo (*USA*)

15:40 **Large Scale Suicide Prevention by Pharmacological Treatment of Mood Disorders**  
 E. Isometsa (*Finland*)

16:00 **Brain Imaging Biomarkers in Personalizing Pharmacotherapy of Suicidal Depressed Patients**  
 J.J. Mann (*USA*)

16:20 **Discussion**

**15:00 – 16:30 Roma Hall**

## Joint Symposium:

**World Psychiatry in 2020 – Where we are and Where we Need to go – Joint Symposium with the WPA**

 Chairs: D. Bhugra (*United Kingdom*)  
 W. Gaebel (*Germany*)

- 15:00 **Challenges for World Psychiatry in 2016**  
 D. Bhugra (*United Kingdom*)
- 15:20 **Contributions of European Psychiatry to World Psychiatry**  
 W. Gaebel (*Germany*)
- 15:40 **How can Biological Psychiatry Contribute to World Psychiatry?**  
 M. Takeda (*Japan*)
- 16:00 **Social Psychiatry in a Global Perspective**  
 T.J. Craig (*United Kingdom*)
- 16:20 **Discussion**

**15:00 – 16:30 Paris Hall**

## Symposium:

**Market Economy and its Consequences for Mental Health**

 Chairs: M. Kastrup (*Denmark*)  
 N. Sartorius (*Switzerland*)

- 15:00 **Mental health in context. Impact of economic policies on health services**  
 N. Sartorius (*Switzerland*)
- 15:20 **Overview of the EPA Guidance Paper**  
 M.M. Carrasco (*Spain*)
- 15:40 **Choosing Wisely Initiative**  
 S. Bailey (*United Kingdom*)
- 16:00 **Discussant: Ethical Challenges**  
 M. Kastrup (*Denmark*)
- 16:20 **Discussion**

**15:00 – 16:30 La Habana Hall**

## Oral Communications:

**Cognitive Neuroscience, Genetics and Molecular Neurobiology, Neuroimaging, Psychoneuroimmunology**

 Chair: M. Kyriakopoulos (*United Kingdom*)

- 15:00 **The EVACO Project: A New Battery for Assessing Social Cognition Disorders and Related Psychiatric Disability in Schizophrenia**  
 P. Roux (*France*)
- 15:09 **A Novel Protocol to Assess Dual Task Cost as a Potential Measure of Cognitive Reserve**  
 A. Oliveira-Maia (*Portugal*)
- 15:18 **Cortisol, Life Events and Cognition in Non-Demented Subjects: A Population-Based Study**  
 S. Ouanez (*Tunisia*)
- 15:27 **Potential Blood Gene Expression Markers for Postpartum Psychosis**  
 M. Fuste (*United Kingdom*)
- 15:36 **A Meta-Analysis of Gene (5-HTT) x Environment Interactions in Eating Pathology using Secondary Data Analyses**  
 I. Krug (*Australia*)
- 15:45 **Parkinsonism and Basal Ganglia Volumes in First Episode Psychosis**  
 M. Cuesta (*Spain*)
- 15:54 **The Role of Neurometabolites in Emotional Processing**  
 D. Denzel (*Germany*)
- 16:03 **Association Analysis of Imbalanced Interhemispheric Functional Coordination and Early Therapeutic Efficacy in Major Depressive Disorder: Evidence from Resting State fMRI**  
 Z. Hou (*China*)
- 16:12 **Alteration in Creatine Phosphate Behavior in Excited Visual Cortex of Early-Stage Schizophrenia Patients Measured by Phosphorus Magnetic Resonance Spectroscopy**  
 A. Manzhurtsev (*Russia*)
- 16:21 **Trimodal Approach (PET/MR/EEG) of Response Inhibition as a Possible Biomarker for Schizophrenia**  
 C. Wyss (*Switzerland*)

**15:00 – 18:30**   **Berlín Hall**

EPA Course:

**The Pharmacological Management of Mood Disorders and Psychoses in Pregnancy and Lactation**

 A. Wieck (*United Kingdom*)

**15:00 – 18:30**  **Bratislava Hall**

EPA Course:

**Behavior Addictions: Internet and Exercise Addiction in Focus**

 Z. Demetrovics (*Hungary*)

 T. Kurimay (*Hungary*)

**15:00 – 16:30** **Amsterdam Hall**

Oral Communications:

**Epidemiology and Social Psychiatry, Mental Health Policies, Others, Personality and Personality Disorders, Posttraumatic Stress Disorder, Prevention of Mental Disorders, Suicidology and Suicide Prevention, TeleMental Health**

 Chair: M.P. García-Portilla Gonzalez (*Spain*)

**15:00 A Multi-Attribute Utility Instrument Suitable for Use in Individuals with Psychosis – the AQoL-4D: Findings from the Second Australian National Survey of Psychosis**

 A. Neil (*Australia*)

**15:06 Loneliness Is Adversely Associated with Lifestyle and Physical and Mental Health**

 A. Richard (*Switzerland*)

**15:12 Changes in Prescribing Patterns of Benzodiazepines after Training of General Practitioners**

 T. Alves-dos-Reis (*Portugal*)

**15:18 Differences between Countries in Adult Acute Psychiatric Hospitalization: Clinical Features and Drug Prescription in Spain and the United States of America**

 L. Gonzalez-Blanco (*Spain*)

**15:24 Prevalence, Mortality and Healthcare Utilization of Cluster B Personality Disorders in Quebec: A Province Cohort Study, 2001-2012**

 L. Cailhol (*Canada*)

**15:30 Correlation between Attachment and Personality Dimensions and their Association to the Catechol-O-Methyltransferase Val158Met Polimorphism**

 L. Erkoreka (*Spain*)

**15:36 Traumatic Stress and Risk of Severe Mental Illness: A Nationwide Cohort Study**

 N. Okkels (*Denmark*)

**15:42 Co-Occurrence of PTSD and Cardiovascular Disease among Ethnic/Racial Groups in the United States**

 C. Vidal Mariño (*Spain*)

**15:48 Prevalence of the Metabolic Syndrome in Patients at Risk of Psychosis**

 J. Cordes (*Germany*)

**15:54 The Effects of the Last Global Economic Crisis on the Suicide Rate in Europe**

 M.M. Dumitru (*Romania*)

**16:00 Childhood Trauma in Suicide Attempters: Case Control Study**

 L. Jimenez-Trevino (*Spain*)

**16:06 Profile of Users of a New E-Mental Health Ecological Momentary Assessment Web-Based Program: MEmind**

 C. Bonal Giménez (*Spain*)

**16:12 A Randomized Controlled Trial of an Internet-Delivered Treatment: Its Potential as a Low-Intensity Community Intervention for Adults with Symptoms of Depression**

 D. Richards (*Ireland*)

**15:00 – 16:30**
**EECP**
**La Paz Hall**

Early Career Psychiatrists:

**Court Debates – Mindful Or Mindless: Is Mindfulness more than Just a Hype?**

 Chairs: N. Jovanovic (*Croatia*)  
 G. Lydall (*United Kingdom*)

**Con**

 Opponent: T. Kashdan (*USA*)

**Pro**

 Defendant: W. Kuyken (*United Kingdom*)

**Judge**

 F. Hohagen (*Germany*)

**16:30 – 17:00**
**Coffee Break, e-Poster Viewing & Visit the Exhibition**
**17:00 – 18:30**
**Auditorium A**

Symposium:

**Lifespan Development of Schizophrenia and How the Treatments Improve Outcome**

 Chairs: M. Isohanni (*Finland*)  
 H. Koponen (*Finland*)

 17:00 **A Life Course Perspective on Familial and Environmental Risks for Schizophrenia Using a Western Australian E-Cohort**

 V. Morgan (*Australia*)

 17:20 **Somatic Comorbidity and Its Outcomes in Schizophrenia during Lifespan**

 J. Seppala (*Finland*)

 17:40 **Treatment-Resistant Schizophrenia during Life Span: Epidemiology, Outcomes and Innovative M-Health Treatments, within M-RESIST Project**

 K. Rubinstein (*Israel*)

 18:00 **Antipsychotic Medication and Outcomes in Schizophrenia from a Lifespan Perspective**

 H. Koponen (*Finland*)

 18:20 **Discussion**

**17:00 – 18:30** **Madrid Hall**

## Symposium:

**Value Based Health Care**

 Chairs: W. Gaebel (*Germany*)  
 F. Van Eenennaam (*The Netherlands*)

- 17:00 **Value-Based Healthcare: The European Experience**  
 F. Van Eenennaam (*The Netherlands*)
- 17:20 **Value-Based Mental Healthcare: The Quality Aspect**  
 W. Gaebel (*Germany*)
- 17:40 **Value-Based Mental Healthcare: The Cost Aspect**  
 M. Knapp (*United Kingdom*)
- 18:00 **Value in Mental Healthcare: The Patient Aspect**  
 Y. Cohen (*Israel*)
- 18:20 **Discussion**

**17:00 – 18:30** **Roma Hall**

## Symposium:

**Bipolar Disorders: From Detection to Intervention**

 Chairs: M. Tremblay (*United Kingdom*)  
 S. Frangou (*USA*)

- 17:00 **Developmental Trajectories to Bipolar Disorder**  
 S. Frangou (*USA*)
- 17:20 **The Bipolar Expert Centres; A French Network for Care and Research**  
 C. Henry (*France*)
- 17:40 **Implementing the Clinical Standards of the National Institute for Health and Care Excellence (NICE) Bipolar Clinical Guideline**  
 M. Tremblay (*United Kingdom*)
- 18:00 **Protecting the Cardiometabolic Health of Young People Experiencing Psychosis**  
 D. Shiers (*United Kingdom*)
- 18:20 **Discussion**

**17:00 – 18:30** **Londres Hall**


## Symposium:

**Hallucinations and Delusions in Schizophrenia: From Phenomenology to Neurobiology**

 Chairs: S. Galderisi (*Italy*)  
 M. Musalek (*Austria*)

- 17:00 **Abnormal Time Experience, Bizarre Delusions and Verbal-Acoustic Hallucinations in Schizophrenia**  
 G. Stanghellini (*Italy*)
- 17:20 **Hallucinations without Delusions in Patients with First-Episode Psychosis: Clinical Correlates and Implications for Pathophysiological Models**  
 I. Melle (*Norway*)
- 17:40 **Accounting for the Phenomenology and Varieties of Auditory Verbal Hallucinations within a Predictive Processing Framework**  
 S. Wilkinson (*United Kingdom*)
- 18:00 **Brain Imaging Contribution to Neurobiological Models of Auditory Hallucinations**  
 T. Dierks (*Germany*)
- 18:20 **Discussion**

**17:00 – 18:30** **Paris Hall**

## Workshop:

**Old Age Psychiatry – Towards the Future**

 Chairs: G. Stoppe (*Switzerland*)  
 M.M. Carrasco (*Spain*)

- 17:00 **Old and New Reasons for Specialisation**  
 G. Stoppe (*Switzerland*)
- 17:10 **Old Age Psychiatry in the 21<sup>st</sup> Century: Old Principles, New Challenges**  
 R. Mateos (*Spain*)
- 17:20 **Training in Old Age Psychiatry: The 30 Countries' Perspective**  
 M. Orrell (*United Kingdom*)
- 17:30 **Harmonisation of European Training**  
 R. Oude Voshaar (*The Netherlands*)
- 17:40 **Discussion**

**17:00 – 18:30** **Amsterdam Hall**

## Workshop:

**Child and Adolescent Mental Health Services in Europe: The Current Scenario and the Future Prospects**

 Chairs: S. Singh (*United Kingdom*)  
 G. de Girolamo (*Italy*)

- 17:00 **The Current State of Child and Adolescent Mental Health Services in Europe: A Survey in 28 Countries**  
 G. de Girolamo (*Italy*)
- 17:10 **Novel Research on Transition from Child to Adult Mental Health Services in Europe: The MILESTONE Project**  
 H. Tuomainen (*United Kingdom*)
- 17:20 **A Systematic Review of Service Transitions in People with ADHD**  
 F. McNicholas (*Ireland*)

- 17:30 **Becoming a Psychiatrist: Who is Trained in the Transition from Child to Adult Psychiatry? A Systematic Review of Training Models in Europe**  
 S. Tremmery (*Belgium*)
- 17:40 **Developing and Measuring Transition-Related Decision-Making in Europe**  
 P. Santosh (*United Kingdom*)
- 17:50 **Discussion**

**17:00 – 18:30** **S** **La Habana Hall**

## Workshop:

**Suicide Risk Evaluation: From Research to Clinical Practice**

 Chairs: D. Wasserman (*Sweden*)  
 M. Sarchiapone (*Italy*)

- 17:00 **Risk Assessment of Suicidal Behaviours: Recent Findings**  
 M. Sarchiapone (*Italy*)
- 17:10 **Electrodermal Hyporeactivity Evaluation for Detecting Suicidal Propensity in Depressed Patients**  
 L.H. Thorell (*Sweden*)
- 17:20 **New Technologies for Detecting Suicidal Risk of Psychiatric Patients**  
 J.L. Castroman (*France*)
- 17:30 **Future Direction of Suicidal Risk Assessment**  
 H. Blasco-Fontecilla (*Spain*)
- 17:40 **Discussion**

**17:00 – 18:30** **La Paz Hall**

Oral Communications:

**Schizophrenia – Part 1**

 Chair: D. Palao Vidal (*Spain*)

**17:00 Differential Serum Acute-Phase Biomarker Profile in Schizophrenia and Bipolar Disorder**

 B. Arranz (*Spain*)

**17:05 Cognitive Function in Female Patients with Schizophrenia and Metabolic Syndrome**

 A.C. Botis (*Romania*)

**17:10 An Interventional, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Active Reference, Flexible Dose Study of Brexpiprazole in Adults with Acute Schizophrenia**

 M. Hakala (*Denmark*)

**17:15 Life-Time Antipsychotic Use and Brain Structures in Schizophrenia and Other Psychoses – 43-Year Study of the Northern Finland Birth Cohort 1966**

 S. Huhtaniska (*Finland*)

**17:20 Maternal Obstetric Complications and Intellectual Functioning in Patients with Schizophrenia and Their Healthy Siblings**

 H. Karakula-Juchnowicz (*Poland*)

**17:25 Disrupted Thalamo-Orbitofrontal but Not Fronto-Temporal White Matter Connectivity in People with Schizotypal Personality Disorder**

 T.Y. Lee (*Republic of Korea*)

**17:30 Methylenetetrahydrofolate Reductase (MTHFR) Gene Polymorphisms and Antipsychotic-induced Metabolic Disturbances in First-episode Schizophrenia Patients**

 B. Misiak (*Poland*)

**17:35 Effectiveness of Long-Acting Injectables and Clozapine in a Real-World Setting during the Early Stages of Psychotic Illness**

 E.G. Ostinelli (*Italy*)

**17:40 An Observational Study of Clozapine Induced Sedation and its Pharmacological Management**

 S. Ramos Perdigues (*Spain*)

**17:45 Assessment of Cognitive Impairment with the Cognitive Assessment Interview (CAI) was useful for Identifying Poor Psychosocial Functioning Outcome in Patients with Psychosis**

 A. Sánchez (*Spain*)

**17:50 Cerebral Hemodynamics in Schizophrenia During the Trail Making Test: A Functional Transcranial Doppler Sonography Study**

 S. Egger (*Switzerland*)

**17:55 Does Family History of Schizophrenia Affect the Severity of Disease**

 M. Sisek-Šprem (*Croatia*)

**18:00 Soluble Fas ligand (sFasL) as a Predictor of Reduction of General Psychopathology in Schizophrenia after Antipsychotic Treatment**

 K. Szymona (*Poland*)

**18:05 Basic Symptoms as Subjective Cognitive Deficit in Schizophrenia: Cognitive, Clinical and Functional Associations**

 M. Vargas (*Spain*)

**18:10 Adjunctive Memantine in Clozapine-Treated Refractory Schizophrenia: A One-Year Extension Study**

 S. Veerman (*The Netherlands*)

**18:15 Efficacy and Safety of Brexpiprazole in Schizophrenia: Meta-Analysis of Three Double-Blind, Randomized, Placebo-Controlled Phase 3 Studies**

 C. Weiss (*USA*)



## YOU'VE ONLY JUST ARRIVED & ALREADY WE'RE THINKING OF YOUR NEXT TRIP

As the official airline network for the 24th European Congress of Psychiatry, we'd like to thank you for choosing the Star Alliance network and hope that all goes really well for you here today.

Whilst you concentrate on the day's events, we hope you'll consider us the next time you need to attend a conference.

With over 18,500 flights a day to 1,330 airports across 192 countries, our 28 member airlines will extend a wide choice of flights to any future conference you're planning to attend. And no matter which of those airlines' frequent flyer programmes you belong to, you can earn and redeem miles across all of them.

So the next time you want to concentrate all your energies on your conference, we hope you'll decide to leave the travel arrangements to us.



EUROPEAN PSYCHIATRIC ASSOCIATION

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

Madrid, Spain 12-15 March 2016  
[www.epa-congress.org](http://www.epa-congress.org)

**TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY**

## SCIENTIFIC PROGRAMME MONDAY, 14 MARCH 2016



Brainsway



Brainsway Deep TMS

# Remission Accomplished

The therapy that can bring even your treatment-resistant depression patients to remission.

**Wine tasting & live demo  
at booth #8**

For more info contact: [marketing@brainsway.com](mailto:marketing@brainsway.com)

## SCIENTIFIC PROGRAMME MONDAY, 14 MARCH 2016

8:00 – 9:30

Auditorium A

Symposium:

**European Alliances Against Depression: 4-Level Interventions Targeting Depression and Suicidal Behaviour**

Chairs: U. Hegerl (*Germany*)

V. Perez (*Spain*)

8:00 **Community-Based 4-Level Approach: Background, Implementation and Evidence for Efficacy**

U. Hegerl (*Germany*)

8:20 **Training in the Context of Multilevel Suicide Prevention Programmes – An International Perspective**

E. Arensman (*Ireland*)

8:40 **Evaluation of the First Year Experience of the Suicide Risk Code in the Emergency Room – A Case Study from Spain**

V. Perez (*Spain*)

9:00 **Sustainability of Training Effects in Primary Care at a National Level: EEA Grants Implementation in Portugal**

R. Gusmão (*Portugal*)

9:20 **Discussion**

---

**8:00 – 9:30** **Madrid Hall**


---

Symposium:

**Epigenetic Discoveries in Psychiatric Disorders**

 Chairs: P. Gorwood (*France*)  
 N. Ramoz (*France*)

- 8:00 **Methylome Modifications in Monozygotic Twins and in Depression**  
 L. Fananas (*Spain*)
- 8:20 **Whole Genome Epigenetic Changes Genome Regarding Childhood Maltreatment in Patients with Borderline Personality Disorder or Depression**  
 L. Stenz (*Switzerland*)
- 8:40 **Longitudinal Study of Methylome Profiles in Subjects with Psychosis and/or Schizophrenia**  
 O. Kebir (*France*)
- 9:00 **Epigenetic Modifications in Anorexia Nervosa Patients and Remitters Compared to Healthy Control Women**  
 N. Ramoz (*France*)
- 9:20 **Discussion**

---

**8:00 – 9:30** **Roma Hall**


---

Symposium:

**Mental Health in Nursing Homes: Current Best Practice**

 Chairs: R. Heun (*United Kingdom*)  
 F. Riese (*Switzerland*)

- 8:00 **Organizing Mental Health Care in Nursing Homes: How, by Whom and What for?**  
 C.A. de Mendonça Lima (*Switzerland*)
- 8:20 **Mental Health of Swiss Nursing Home Residents: Epidemiological Data from the ZULIDAD Study**  
 F. Riese (*Switzerland*)
- 8:40 **Treating Chronically Psychotic Patients in Nursing Homes**  
 J. Gauillard (*France*)

- 9:00 **Modell Donaustadt: A Best-Practice Example for Treatment of Mental and Physical Comorbidity in Long-Term Care**  
 B. Hobl (*Austria*)

- 9:20 **Discussion**

---

**8:00 – 9:30** **Londres Hall**


---

Symposium:

**Social Anxiety Disorder – From Shyness and Blushing to Brains and Psychotropic Drugs**

 Chairs: D. Baldwin (*United Kingdom*)  
 I. Iancu (*Israel*)

- 8:00 **The Relationship between Social Anxiety, Shyness and Blushing**  
 A. Pelissolo (*France*)
- 8:20 **Oxytocin in Social Anxiety: An Overview**  
 I. Iancu (*Israel*)
- 8:40 **Neuroimaging Studies in Social Anxiety Disorder: A Glimpse to the Future**  
 A. Bruehl (*Switzerland*)
- 9:00 **Recent Guidelines for Evidence-Based Pharmacological Treatment of Social Anxiety Disorder**  
 D. Baldwin (*United Kingdom*)
- 9:20 **Discussion**

**8:00 – 9:30**  **Paris Hall**

Symposium:

**Offenders with Intellectual Disability: Best Practice Update**

 Chairs: J. McCarthy (*United Kingdom*)  
 B. Völlm (*United Kingdom*)

- 8:00 **Assessment of People with Intellectual Disability for the Court: What does a Psychiatrist need to know?**  
 R. Latham (*United Kingdom*)
- 8:20 **Sex Offenders and Intellectual Disability**  
 K. Goethals (*Belgium*)
- 8:40 **Use of Risk Assessment Tools for People with Intellectual Disability: The Latest Evidence**  
 C. Morrissey (*United Kingdom*)
- 9:00 **Prisoners with Intellectual Disability: How to Adapt Interventions and the Environment**  
 V. Tort Herrando (*Spain*)
- 9:20 **Discussion**



**8:00 – 9:30**  **Amsterdam Hall**

Workshop:

**The Assessment of Negative Symptoms: Achievements and Perspectives**

 Chairs: S. Galderisi (*Italy*)  
 W. Gaebel (*Germany*)

- 8:00 **Evolution of Negative Symptom Assessment Instruments**  
 M.P. García-Portilla Gonzalez (*Spain*)
- 8:10 **Assessment of Negative Symptoms Beyond Schizophrenia**  
 S. Kaiser (*Switzerland*)
- 8:20 **The Second-Generation Assessment Scales: Brief Negative Symptom Scale and Clinical Assessment Interview for Negative Symptoms**  
 A. Mucci (*Italy*)
- 8:30 **Self-Assessment Instruments: Development and Validation**  
 S. Dollfus (*France*)
- 8:40 **Discussion**

**8:00 – 11:30**   **Berlin Hall**

EPA Course:

**Motivational Interviewing in Addiction: How can we Help Patients Change Behaviour and Habits?**

 L. De Backer (*Belgium*)  
 E. Baron (*The Netherlands*)

**8:00 – 9:30**

**Floor 3 Foyer**
**Ask the Experts**

Ask the Experts sessions will allow participants to meet in a small group with outstanding researchers and clinicians. The format is designed to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. Sessions will take place at round tables and be limited to a certain number of participants with advanced sign up required.

**Depression in the Elderly**

G. Stoppe (Switzerland)

**The Use of Antidepressant in Children and Adolescents**

G. Zalsman (Israel)

**Treating ADHD and Addiction in Youngsters and in Adults**

W. van den Brink (The Netherlands)

**Treatment of Alcohol Dependence**

K. Mann (Germany)

Invited Experts and Topics are subject to change.

**8:00 – 9:30**

**La Paz Hall**

Early Career Psychiatrists:

**Court Debates – Should Gender Identity Disorder Should be Considered a Mental Illness?**

Chairs: M. Rojnic Kuzman (Croatia)

S. Nikolic Lalic (Serbia)

**Con**

Opponent: R.J. van der Gaag (The Netherlands)

**Pro**

Defendant: K. Kosidou (Sweden)

**Judge**

M. Waldinger (The Netherlands)

**9:30 – 10:00**
**Coffee Break, e-Poster Viewing and Exhibition**
**10:00 – 11:30**
**Auditorium A**

Debate:

**The Name of Schizophrenia Should be Omitted**

Chair: N. Sartorius (Switzerland)

**Pro**

A. Lasalvia (Italy)

**Con**

M. Davidson (Israel)

**10:00 – 11:30**
**Madrid Hall**

Symposium:

**Overcoming the Stigma of Mental Illness: Current Proceedings and Initiatives**

Chairs: W. Gaebel (Germany)

S. Evans-Lacko (United Kingdom)

 10:00 **Promoting Stigma Coping and Empowerment: Results from the Multi-Center Clinical Trial STEM**

W. Gaebel (Germany)

 10:20 **Reducing Stigma and Social Exclusion: State of the Art in European Research**

S. Evans-Lacko (United Kingdom)

 10:40 **Seven Years after Ratification of the UNCRPD – How can we Progress Toward Making these Ideals a Reality?**

Y. Cohen (Israel)

 11:00 **Mental Illness through the Carers' Eyes. Perception of Stigma from Relatives of People Affected by Mental Diseases**

B. Johnson (Belgium)

 11:20 **Discussion**

**10:00 – 11:30** **Roma Hall**

Joint Symposium:

**Psychiatry in Humanitarian Emergencies – Joint Symposium with the WHO**

 Chairs: M. Muijen (*Denmark*)  
 M. Maj (*Italy*)

- 10:00 **Overview of European Refugee Mental Health Situation**  
 M. Muijen (*Denmark*)
- 10:20 **Internally Displaced Persons in Ukraine**  
 V. Korostiy (*Ukraine*)
- 10:40 **A New Humanitarian Emergency: Refugees and Mental Health in Turkey**  
 L. Küey (*Turkey*)
- 11:00 **Discussion**

**10:00 – 11:30** **Londres Hall**

Symposium:

**Sub-Threshold Psychotic Experiences in the General Population. Predictors for the Development of Psychotic Disorders?**

 Chairs: W. Rössler (*Switzerland*)  
 C. Schmidt-Kraepelin (*Germany*)

- 10:00 **Prevention of Psychotic Disorders in the General Population**  
 W. Rössler (*Switzerland*)
- 10:20 **Psychotic Experiences as Precursors in Schizophrenia?: Findings from a Population Based Sample in Germany (DEGS1-MH)**  
 C. Schmidt-Kraepelin (*Germany*)
- 10:40 **Clinic Risk Associated with Comorbidity of (Subclinical) Psychosis, Anxiety and Depressive Symptoms: A Case for Stratified Medicine in Psychiatry**  
 M. van Nierop (*The Netherlands*)
- 11:00 **Exploring Full-Blown Psychotic Experiences in 'Non-Need for Care' Populations: Findings from the UNIQUE Study**  
 E. Peters (*United Kingdom*)
- 11:20 **Discussion**

**10:00 – 11:30** **Paris Hall**


Early Career Psychiatrists:

**Workshop: Getting Started: The First Steps in Psychiatric Consultations**

 Chairs: A. Barbosa (*Portugal*)  
 O. Kazakova (*Belarus*)

- 10:00 **The Magic List of Everyday Problems in Consultation-Liaison Psychiatry (and Hints for Solving Them)**  
 S. Ferrari (*Italy*)
- 10:10 **Short-Term Psychotherapeutic Interventions in Consultation-Liaison Psychiatry**  
 A. Diefenbacher (*Germany*)
- 10:20 **Drugs Pharmacokinetics Interactions with Cardiac and Renal Disease Patients in Consultation-Liaison Psychiatry**  
 D. Telles (*Portugal*)
- 10:30 **Psychopharmacological Treatments Strategies in Consultation-Liaison Psychiatry: Clinical Vignette and Pros & Cons**  
 G. Mattei (*Italy*)
- 10:40 **Psychotherapeutic Interventions in Consultation-Liaison Psychiatry Implications for Psychiatric Trainees**  
 K. Koelkebeck (*Germany*)
- 10:50 **Discussion**

**10:00 – 11:30** **Amsterdam Hall**

Oral Communications:

**Psychopharmacology and Pharmacoeconomics, Psychosurgery and Stimulation Methods (ECT, TMS, VNS, DBS), Sleep Disorders and Stress, Treatment Practice**

 Chair: G. Serafini (*Italy*)

 10:00 **Impact of DRD2 Polymorphisms on Prolactin Level in Risperidone-Treated Thai Children and Adolescent with Autism Spectrum Disorders**

 C. Sukasem (*Thailand*)

 10:09 **Detection of CYP2D6 Polymorphism Using Luminex xTAG Technology in Autism Spectrum Disorder: CYP2D6 Activity Score and Its Association with Risperidone Levels**

 C. Sukasem (*Thailand*)

 10:18 **Angiotensin II Type 1 Receptor Blockade Diminishes Negative Effect of Chronic Stress on Memory via Up-Regulation of Brain-Derived Neurotrophic Factor**

 D. Wincewicz (*Poland*)

 10:27 **Neuropsychiatric Consequences of Deep Brain Stimulation Surgeries in the Patients Affected by Chronic Movement Disorders: A Brief Report**

 S. Mahdavi (*Iran*)

 10:36 **Transcranial Direct Current Stimulation in Treatment- Resistance Unipolar Major Depressive Disorder**

 A. Mina (*Iran*)

 10:45 **Cryostimulation of Whole Body as a Possible Supportive Biological Approach in Mild Cognitive Impairments**

 J. Rymaszewska (*Poland*)

 10:54 **Sleep Disturbances and Substance Use Disorders: An International Study of Primary Care and Mental Health Specialty Care Patients**

 L. Fortuna (*USA*)

 11:03 **Sensory Hypersensitivity Predicts Reduced Sleeping Quality in Patients with Major Affective Disorders**

 G. Serafini (*Italy*)

 11:12 **Association Between Circadian Rhythm, Sleep Disturbances and Temperament in Major Depression, Bipolar Disorder and Schizophrenia**

 S. Tunç (*Turkey*)

 11:21 **Preventing Weight Gain and Increased Waist Circumference During the First Two Years After Anti-Psychotic Initiation in Youth with First Episode Psychosis**

 P. Ward (*Australia*)

**10:00 – 11:30**

**Floor 3 Foyer**
**Ask the Experts**

Ask the Experts sessions will allow participants to meet in a small group with outstanding researchers and clinicians. The format is designed to facilitate informal discussions, allowing participants to present their questions and gain new perspectives. Sessions will take place at round tables and be limited to a certain number of participants with advanced sign up required.

**Suicide Prevention**

 D. Wasserman (*Sweden*)

**Psychotherapy Training in Psychiatry**

 F. Hohagen (*Germany*)

**The Experiential Dimension in Severe Mental Disorders**

 G. Stanghellini (*Italy*)

**Integrating Personality Traits in Clinical Practice**

 P. Tyrer (*United Kingdom*)

Invited Experts and Topics are subject to change.

**10:00 – 11:30** **EECP** **La Paz Hall**

Early Career Psychiatrists:

**Identity Or Competency: How to Train the Modern Day Psychiatrist**

 Chairs: M. Pinto da Costa (*Portugal*)  
 G. Dom (*Belgium*)

- 10:00 **Should all Psychiatrists be Skilled to Practice Psychotherapy?**  
 E. Sönmez (*Turkey*)
- 10:10 **Should all Psychiatrists be Skilled to Practice Psychotherapy?**  
 T. Gargot (*France*)
- 10:20 **Is Addiction Medicine Part of Psychiatry?**  
 L. Orsolini (*Italy*)
- 10:40 **Do CAP and Adult Psychiatrists Share a Common Identity?**  
 I. Viltrakyte (*Lithuania*)
- 10:50 **Do CAP and Adult Psychiatrists Share a Common Identity?**  
 A. Kanellopoulos (*Greece*)
- 11:00 **The Tension between Identity and Competency: Comparing Behavioural and Constructionist Approaches to Professional Formation**  
 A. Brittlebank (*United Kingdom*)
- 11:20 **Discussion**

**11:30 – 11:45**
**Short Break**
**11:45 – 12:30** **Auditorium A**

Plenary:

**Can we Learn from Developing Countries to Improve Our Own Practice?**

 Chair: D. Wasserman (*Sweden*)

- 11:45 **Can we Learn from Developing Countries to Improve our own Practice?**  
 V. Patel (*India*)

**12:30 – 13:15**
**Break, e-Poster Viewing, e-Poster Walks & Exhibition**
**13:15 – 14:45** **Londres Hall**
**Satellite Symposium 3 – Not Included in the Main Event CME/CPD**
**14:45 – 15:00**
**Short Break**
**15:00 – 15:45** **Auditorium A**

State-of-the-Art:

**Chronic Depression: Psychotherapeutic Approach**

 Chair: A. Heinz (*Germany*)

- 15:00 **Chronic Depression: Psychotherapeutic Approach**  
 C. Bockting (*The Netherlands*)

**15:45 – 16:30 Auditorium A**

State-of-the-Art:

**Nutrition, Sleep, Physical Exercise: Impact on Mental Health**

 Chair: G. Dom (*Belgium*)

- 15:45 **Nutrition, Sleep, Physical Exercise: Impact on Mental Health**  
 W. Rössler (*Switzerland*)

**15:00 – 16:30 S Madrid Hall**

Workshop:

**Future Experts on the Floor: Young Researchers in Addiction**

 Chairs: L. De Backer (*Belgium*)  
 D. Papanti (*Italy*)

- 15:00 **Neurostimulation in Alcohol Dependence: The Effect of Repetitive Transcranial Magnetic Stimulation on Brain Function and Craving**  
 J. Jansen (*The Netherlands*)
- 15:10 **Translational Perspectives in Addiction Psychiatry**  
 A. Schellekens (*The Netherlands*)
- 15:20 **Novel Psychoactive Substances**  
 L. Orsolini (*Italy*)
- 15:30 **The Impact of Appetite Regulating Peptides on Substance Use Disorders**  
 A. Koopmann (*Germany*)
- 15:40 **Discussion**

**15:00 – 16:30 Roma Hall**

Symposium:

**Self-Related Processes and Underlying Brain Networks: Relevance for Major Psychiatric Disorders**

 Chairs: A. Aleman (*The Netherlands*)  
 G. Northoff (*Canada*)

- 15:00 **Psychopathology of the Self and the Altered Cortical Midline Structures in Psychiatric Disorders – A Marriage?**  
 G. Northoff (*Canada*)
- 15:20 **The Social Self in Schizophrenia: A Neural Network Perspective on Integrative External and Internal Information Processing**  
 S. Ebisch (*Italy*)
- 15:40 **Brain Networks Sub serving Self-Referential Processing in Depression**  
 G. Wagner (*Germany*)
- 16:00 **Self-Related Networks and Negative Symptoms in Psychotic Disorders**  
 A. Aleman (*The Netherlands*)
- 16:20 **Discussion**

**15:00 – 16:30** **Londres Hall**

## Symposium:

**Field Studies Version of the ICD-11 Classification of Mental and Behavioural Disorders: Development, Rationale, and Public Release**

 Chairs: W. Gaebel (*Germany*)  
 G. Reed (*Switzerland*)

- 15:00 **The New Field Studies Version of the ICD-11 Classification of Mental and Behavioural Disorders: Request for Comments**  
 G. Reed (*Switzerland*)
- 15:20 **Prospects for Including Findings from Neuroscience and Genetics in a Clinical and Public Health Classification of Mental Disorders**  
 D. Stein (*South Africa*)
- 15:40 **Incorporating Dimensional Constructs in the ICD-11 Categorical Classification: The Examples of Psychotic and Personality Disorders**  
 W. Gaebel (*Germany*)
- 16:00 **Incorporating Global and Cultural Perspectives in the ICD-11 Classification of Mental and Behavioural Disorders**  
 O. Gureje (*Nigeria*)
- 16:20 **Discussion**

**15:00 – 16:30** **Paris Hall**

## Workshop:

**How to Overcome the Negative Image of Psychiatry: Facts and Fiction**

 Chairs: P. Falkai (*Germany*)  
 I. Hauth (*Germany*)

- 15:00 **The Negative Image Psychiatry from a Sociological Perspective**  
 A.M. Möller-Leimkühler (*Germany*)
- 15:10 **The Negative Image of Psychiatry in the Medical Community**  
 R.J. van der Gaag (*The Netherlands*)
- 15:20 **Are Psychiatrists an Endangered Species?**  
 H. Katschnig (*Austria*)
- 15:30 **Why Medicine Needs Psychiatry**  
 S. Wessely (*United Kingdom*)
- 15:40 **First Data from a Survey Comprising the Representatives of the NPA Council of the EPA**  
 P. Vallon (*Switzerland*)
- 15:50 **Discussion**

**15:00 – 16:30** **Amsterdam Hall**

Oral Communications:

**Schizophrenia – Part 2**

 Chair: M. Bernardo Arroyo (*Spain*)

- 15:00 **Clinical Symptomatology and Facial Emotion Recognition in Schizophrenia: Which Relationship?**  
 A. Arous (*Tunisia*)
- 15:05 **Akathisia: Prevalence and Risk Factors in a Community-Dwelling Sample of Patients with Schizophrenia. Results From the Multi-Center FACE-SZ Data Set**  
 F. Berna (*France*)
- 15:10 **Antipsychotic-Induced Tardive Dyskinesia: The Role of Glutamatergic System**  
 A. Boiko (*Russia*)
- 15:15 **Comparing Cognitive Functions in Medication Adherent and Non-Adherent Patients with Schizophrenia**  
 A. El-Missiry (*Egypt*)
- 15:20 **Abnormal Connectivity in Dorsolateral Prefrontal Cortex in Schizophrenia Patients and Unaffected Relatives**  
 L. Galindo (*Spain*)
- 15:25 **Are Self-Stigma and Coping Strategies Interrelated in Outpatients with Schizophrenia Spectrum Disorders using the Psychiatric Medication? Cross-Sectional Study**  
 M. Holubova (*Czech Republic*)
- 15:30 **Association between Drug-Induced Hyperprolactinemia Related Adverse Events on Women Schizophrenia Patients with DRD2 Taq1 Polymorphism**  
 D. Jung (*Republic of Korea*)
- 15:35 **Affectivity during Social Behaviour in a Schizophrenic-like Rat**  
 L. Kai (*Denmark*)
- 15:40 **Trends of hospitalization for Schizoaffective Disorder (SD) in USA: A Nationwide Analysis**  
 Z. Mansuri (*USA*)
- 15:45 **Trends of Hospitalization for Schizophrenia in USA: A Nationwide Analysis**  
 Z. Mansuri (*USA*)

- 15:50 **Electrophysiological Mechanisms Underlying ERP Amplitude Reduction in Patients with Schizophrenia: A Time-Frequency Analysis**  
 D. Marasco (*Italy*)
- 15:55 **Clinical Symptomatology and Theory of Mind in Schizophrenia: Which Relationship?**  
 J. Mrizak (*Tunisia*)
- 16:00 **Metabolic Syndrome in Patients with Schizophrenia Receiving Long-Term Treatment with Lurasidone, Quetiapine XR, or Risperidone**  
 A. Pikalov (*USA*)
- 16:05 **Neurochemical and Behavioral Sensitization to d-amphetamine in Healthy Subjects Measured with [11C](+)-PHNO-PET**  
 A. Popovic (*Austria*)
- 16:10 **Trends of Hospitalization for Schizophreniform Disorder in USA: A Nationwide Analysis**  
 M. Rathod (*USA*)
- 16:15 **Decreased Interhemispheric Resting-State Functional Connection in Schizophrenic Patients with Auditory Hallucinations**  
 H. Wang (*China*)
- 16:20 **Premorbid Social Adjustment Is Better in Cannabis-Using than Non-Using Psychotic Patients across Europe**  
 F. Laura (*Italy*)

**15:00 – 18:30**  **Berlin Hall**

EPA Course:

**Supporting Family Members of People with Severe Mental Health Illnesses**

- A. Fiorillo (*Italy*)  
 U. Volpe (*Italy*)

**15:00 – 18:30**  **La Habana Hall**

EPA Course:

**Statistical Methods in Psychiatric Research**

D. Mendonça (*Portugal*)  
 L. Teixeira (*Belgium*)  
 P. Oliveira (*Portugal*)  
 M. Pinto da Costa (*Portugal*)

**15:00 – 16:30**  **La Paz Hall**

Early Career Psychiatrists:

**Training Workshop – Using Ethics in Daily Psychiatry**

Chairs: J.N. Beezhold (*United Kingdom*)  
 C. Hanon (*France*)

**Case Presentation 1**

 F. Riese (*Switzerland*)

**Case Presentation 2**

 E. Valenti (*Spain*)

**16:30 – 17:00**
**Coffee Break, e-Poster Viewing & Visit the Exhibition**
**17:00 – 18:30** **Auditorium A**

Symposium:

**Brain Plasticity in Psychiatry**

Chairs: R.J. van der Gaag (*The Netherlands*)  
 L. Küey (*Turkey*)

**17:00 Gene Environment Interactions and Brain Plasticity**

 T. Paus (*Canada*)

**17:20 ECT related Brain Plasticity and Therapeutic Outcome**

 B. Draganski (*Switzerland*)

**17:40 Relevance of Brain Plasticity to Neuroprogression and Staging of Bipolar Disorders – Opposing Effects of Illness Burden and Lithium Treatment**

 T. Hajek (*Canada*)

**18:00 Brain Connectivity and Plasticity**

 J. Horacek (*Czech Republic*)

**18:20 Discussion**
**17:00 – 18:30** **Madrid Hall**

Symposium:

**Mental Health in Young Women: Are they more at Risk in the 21<sup>st</sup> Century?**

Chairs: H. Herrman (*Australia*)  
 S. Galderisi (*Italy*)

**17:00 Defining Mental Health and Identifying Relevant Components in Young People**

 S. Galderisi (*Italy*)

**17:20 Why Mental Health in Young Women is More at Risk in the 21<sup>st</sup> Century**

 H. Herrman (*Australia*)

**17:40 School Children's Mental Health in Europe: Are there Gender-related Differences?**

 V. Kovess-Masfety (*France*)

**18:00 Early Psychosis in Young Women**

 A. Riecher-Rössler (*Switzerland*)

**18:20 Discussion**

**17:00 – 18:30** **Roma Hall**

Joint Symposium:

**Advancing Implementation – Joint Symposium with European Mental Health Programmes**

 Chairs: I. Peña-Rey (*Luxembourg*)  
 W. Gaebel (*Germany*)

- 17:00 **Recent Results from the Joint Action of Mental Health and Well-Being**  
 J. Caldas de Almeida (*Portugal*)
- 17:20 **What are the Future Perspectives of the ROAMER Project?**  
 J.M. Haro (*Spain*)
- 17:40 **The European Commission's perspective: European Framework for Action and EU Compass on Mental Health and Wellbeing**  
 I. Peña-Rey (*Luxembourg*)
- 18:00 **Implementing the Mental Health Action Plan – Experiences and Challenges**  
 M. Muijen (*Denmark*)
- 18:20 **Discussion**  
 Discussant: G. Morales (*Spain*)

**17:00 – 18:30** **Londres Hall**

Symposium:

**Coercion in Psychiatry: Challenges and Perspectives**

 Chairs: M. Luciano (*Italy*)  
 J.N. Beezhold (*United Kingdom*)

- 17:00 **Using Systems Design to Reduce the Use of Coercion on an Acute Inpatient Ward**  
 J.N. Beezhold (*United Kingdom*)
- 17:20 **Does the Use of Coercion Improve the Outcome of Patients with Severe Mental Disorders?**  
 M. Luciano (*Italy*)
- 17:40 **Young People's Experiences of Coercion and Ideas for Preventing Adverse Pathways to Mental Health Care**  
 S. Evans-Lacko (*United Kingdom*)

- 18:00 **Ethical Challenges in the Use of Coercion**  
 M. Kastrup (*Denmark*)

- 18:20 **Discussion**

**17:00 – 18:30** **Paris Hall**

Symposium:

**The Effects of Neuroleptics on the Brain**

 Chairs: P. Falkai (*Germany*)  
 W. Cahn (*The Netherlands*)

- 17:00 **Discontinuation vs. Continuation Treatment with Neuroleptics for a Better Long-Term Outcome**  
 L. Wunderink (*The Netherlands*)
- 17:20 **GROUP 6 Year Outcome Data in Relation to Antipsychotic Medication**  
 W. Cahn (*The Netherlands*)
- 17:40 **The Effects of Neuroleptics on the Healthy Brain**  
 H. Tost (*Germany*)
- 18:00 **Long-Term Effects of Neuroleptics on the Diseased Brain**  
 N. Koutsouleris (*Germany*)
- 18:20 **Discussion**

**17:00 – 18:30**  **Amsterdam Hall**

Symposium:

**Phenomenology of Anxiety**

 Chairs: G. Stanghellini (*Italy*)  
 M. Aragona (*Italy*)

- 17:00 **Temporality and Spatiality of Anxious Experience**  
 O. Doerr-Zegers (*Chile*)
- 17:20 **Depression and Alcohol Addiction – A Cybernetic Process**  
 M. Musalek (*Austria*)
- 17:40 **Being on the Edge: The Psychopathology of the Accelerated, Agitated and Anxious Subject**  
 L. Madeira (*Portugal*)
- 18:00 **Phenomenology of Emotions**  
 G. Stanghellini (*Italy*)
- 18:20 **Discussion**

**17:00 – 18:30**  **La Paz Hall**

Early Career Psychiatrists:

**Services Users and Carers are Experts in Mental Health**

 Chairs: O. Andlauer (*United Kingdom*)  
 I. Hall (*United Kingdom*)

- 17:00 **Involving People with Intellectual Disabilities in the Formal Assessment of Psychiatrists' Skills**  
 P. Bates (*United Kingdom*)
- 17:20 **Involving People with Intellectual Disabilities in the Formal Assessment of Psychiatrists' Skills**  
 S. Soni (*United Kingdom*)
- 17:40 **From Service User to Mental Health Care Worker: My Experience as a Peer Support Worker**  
 S. Soni (*United Kingdom*)
- 18:00 **Families of Service Users are Expert in Mental Health**  
 B. Johnson (*Belgium*)
- 18:20 **Involving Services Users to Improve Care**  
 D. Giacco (*United Kingdom*)

This image shows a single page of white paper with horizontal blue lines. The lines are evenly spaced and run across the width of the page, typical of notebook paper or a form designed for handwritten entries. There are no margins, text, or other markings on the page.

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

**Madrid, Spain 12-15 March 2016**  
**[www.epa-congress.org](http://www.epa-congress.org)**

TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY

# SCIENTIFIC PROGRAMME

## TUESDAY, 15 MARCH

### 2016

Scientific Programme  
Tuesday 15 March 2016

## SCIENTIFIC PROGRAMME TUESDAY, 15 MARCH 2016

8:00 – 9:30

Roma Hall

Joint Symposium:

**Development of a European Training Curriculum on Psychiatry – Joint Symposium with the Spanish Society of Psychiatry**

Chairs: W. Gaebel (*Germany*)

M.M. Carrasco (*Spain*)

8:00 **Implementing EPA Standards in European National Curricula**

J. Bobes (*Spain*)

8:20 **UEMS Views of a Joint European Curriculum on Psychiatry**

M. Hermans (*Belgium*)

8:40 **Psychiatric Trainees' View on a European Curriculum of Psychiatry**

M. Pinto da Costa (*Portugal*)

9:00 **European Guidance on Training in Psychiatry**

R.J. van der Gaag (*The Netherlands*)

### 18<sup>TH</sup> ANNUAL CONFERENCE OF THE INTERNATIONAL SOCIETY FOR BIPOLAR DISORDERS

Held Jointly with the

### 8<sup>TH</sup> BIENNIAL CONFERENCE OF THE INTERNATIONAL SOCIETY FOR AFFECTIVE DISORDERS

Amsterdam, The Netherlands  
July 13-16, 2016

## Register Early and Save!

[www.isbd2016.com](http://www.isbd2016.com)

#### CONGRESS ORGANIZER

Kenes International  
1-3 Rue de Chantepoulet, PO Box 1726  
CH-1211 Geneva 1, Switzerland  
Tel: +41 22 908 0488  
Fax: +41 22 906 9140  
E-mail: [ISBD@kenes.com](mailto:ISBD@kenes.com)



**8:00 – 9:30** **Berlín Hall**

## Symposium:

**Considering Pain to Better Understand the Suicidal Process**

 Chairs: A. Apter (*Israel*)  
 E. Olie (*France*)

- 8:00 **Pain Perception in Self-Injurious Behaviours**  
 C. Schmahl (*Germany*)
- 8:20 **Neural Pathways of the Association between Pain and Suicide**  
 E. Olie (*France*)
- 8:40 **Psychological Pain and Interpersonal Theory of Suicide**  
 A. Apter (*Israel*)
- 9:00 **Psychological Pain could be Useful for Modelling Suicidal Process**  
 E. Olie (*France*)
- 9:20 **Discussion**

**8:00 – 9:30** **Madrid Hall**

## Workshop:

**Social Cognition in Schizophrenia: Relationship with Neurocognition, Functional Capacity and Functional Outcome**

 Chairs: G. Sachs (*Austria*)  
 A. Mucci (*Italy*)

- 8:00 **Relationships between Neurocognition, Social Cognition and Functional Outcome in Schizophrenia**  
 A. Mucci (*Italy*)
- 8:10 **The Impact of the Different Dimensions of Social Cognition on Functional Outcome in Schizophrenia**  
 P. Rocca (*Italy*)
- 8:20 **Social Cognition, Functional Capacity and Symptoms in the Longitudinal Prediction of Outcome in Subjects with First-Episode Schizophrenia**  
 G. Sachs (*Austria*)

- 8:30 **The Effects of Integrated Treatment with Atypical Antipsychotics and Social Cognition Training on Functional Outcome**  
 G. Sachs (*Austria*)

- 8:40 **Discussion**

**8:00 – 9:30** **Londres Hall**

## Symposium:

**Thought and Language Disorders: Phenomenology and Neural Pathophysiology**

 Chairs: T. Kircher (*Germany*)  
 W. Strik (*Switzerland*)

- 8:00 **Brain Lateralisation, Schizophrenia and Formal Thought Disorder**  
 I. Sommers (*The Netherlands*)
- 8:20 **How increasing the effect of rTMS in the treatment of auditory hallucinations in schizophrenia?**  
 S. Dollfus (*France*)
- 8:40 **Language, Psychosis and the Brain: Novel Insights from a Dimensional Approach**  
 W. Strik (*Switzerland*)
- 9:00 **Phenomenology and Neural Correlates of Formal Thought Disorder**  
 T. Kircher (*Germany*)
- 9:20 **Discussion**

**8:00 – 9:30** **Paris Hall**

Symposium:

**The Role of Emotional Instability in Adult ADHD, Borderline Personality Disorder, Bipolar Disorder, Autism and Intellectual Disability: A Transdiagnostic Construct Or Disorder Specific Syndrome?**

 Chairs: E. Sobanski (*Germany*)  
 J. Ramos-Quiroga (*Spain*)

**8:00 Emotional Instability and Adult Attention Deficit Hyperactivity Disorder (ADHD)**

 P. Asherson (*United Kingdom*)

**8:20 Emotional Instability and Borderline Personality Disorder**

 U. Ebner-Priemer (*Germany*)

**8:40 Emotional Instability and Bipolar Disorder**

 S. Frangou (*USA*)

**9:00 Emotional Instability and Autism and Intellectual Disability**

 J. McCarthy (*United Kingdom*)

**9:20 Discussion**
**8:00 – 9:30** **Amsterdam Hall**

Symposium:

**Does Diet Affect Mental Health? The Role of the Gut-Brain Axis in Psychiatric Disorders**

 Chairs: H. Karakula-Juchnowicz (*Poland*)  
 K.L. Reichelt (*Norway*)

**8:00 Gastroenterology Issues in Schizophrenia: Why the Gut Matters**

 E. Severance (*USA*)

**8:20 The Role of the Gut Microbiota in Mood and Behaviour. Whether Psychobiotics can become an Alternative in Therapy in Psychiatry?**

 E. Pekelharing (*The Netherlands*)

**8:40 Can the Pathophysiology of Autism be Explained by the Nature of the Discovered Urine Peptides and Dietary Antigens?**

 K.L. Reichelt (*Norway*)

**9:00 The Role of IgG Hypersensitivity and Changes in Gut Microbiota in the Pathogenesis and Therapy of Depressive Disorders**

 H. Karakula-Juchnowicz (*Poland*)

**9:20 Discussion**
**8:00 – 9:30** **La Paz Hall**

Early Career Psychiatrists:

**Training Workshop – Dissociative Symptoms, How to Recognise and Treat Them**

 Chairs: M. Kastrup (*Denmark*)  
 N. Jovanovic (*Croatia*)

**Case Presentation 1**

 A. Moscoso (*Portugal*)

**Discussion**

 G. Stanghellini (*Italy*)

**8:00 – 11:30** **La Habana Hall**

EPA Course:

**The Psychotherapy of Anxiety Disorders**

 F. Hohagen (*Germany*)

**9:30 – 10:00**
**Coffee Break, e-Poster Viewing & Visit the Exhibition**

**10:00 – 11:30** **Roma Hall**

## Symposium:

**Sex Matters – Also in Psychosis!**

 Chairs: A. Riecher-Rössler (*Switzerland*)  
 I. Myin-Germeys (*The Netherlands*)

- 10:00 **Sex and Gender Differences in Schizophrenic Psychoses**  
 A. Riecher-Rössler (*Switzerland*)
- 10:20 **Sex Differences in Emotional Reactivity to Daily Life Stress in Psychosis**  
 I. Myin-Germeys (*The Netherlands*)
- 10:40 **Menopause and Psychosis**  
 J. Usall-Rode (*Spain*)
- 11:00 **Sex Differences in the Relationship between Hypothalamic-Pituitary-Adrenal Axis Measures and Cognition in Early Psychosis**  
 J. Labad (*Spain*)
- 11:20 **Discussion**

**10:00 – 11:30** **Berlin Hall**

## Symposium:

**Fighting Against Stigma. A Worldwide Task**

 Chairs: M. Gutiérrez Fraile (*Spain*)  
 F. Ivanovic-Zuvic (*Chile*)

- 10:00 **Stigma in Latin America. The Brazilian Experience**  
 A.G. Da Silva (*Brazil*)
- 10:20 **The Image of European Psychiatry**  
 P. Falkai (*Germany*)
- 10:40 **Campaigning Against Stigma in Spain**  
 M. Roca Bennasar (*Spain*)
- 11:00 **An Antipodean Multicultural View of Stigma: Fear, Prejudice or Discrimination?**  
 M. Hopwood (*Australia*)
- 11:20 **Discussion**

**10:00 – 11:30** **Madrid Hall**

## Symposium:

**Racism and Discrimination in Mental Health Care of Immigrants**

 Chairs: M. Schouler-Ocak (*Germany*)  
 I.T. Graef-Calliess (*Germany*)

- 10:00 **Racism, Discrimination and Migration**  
 K. Bhui (*United Kingdom*)
- 10:20 **Overview of Current Research on Racism and Discrimination in Immigrants**  
 A. Heinz (*Germany*)
- 10:40 **The Impact of Racism and Discrimination on Mental Health of Refugees and Asylum Seekers**  
 M. Kastrup (*Denmark*)
- 11:00 **Room for Hope: How to Deal with Growing Racism and Discrimination?**  
 L. Küey (*Turkey*)
- 11:20 **Discussion**

**10:00 – 11:30** **Paris Hall**

## Workshop:

**Shaping the Future of Healthcare Through Innovation and Technology**

 Chairs: V. Buwalda (*The Netherlands*)  
 S. Saeed (*USA*)

- 10:00 **New Research in Outcome Management Using Apps and DSM-5 Measures. Preliminary Results**  
 V. Buwalda (*The Netherlands*)
- 10:10 **North Carolina Statewide Telepsychiatry Program (NC-SteP): Using Telepsychiatry to Improve Access to Evidence-Based Care**  
 S. Saeed (*USA*)
- 10:20 **21<sup>st</sup> Century House Call Home Tele-Behavioral Medicine**  
 H. Schwager (*USA*)
- 10:30 **Addiction Component Walk along Working towards a New Apps**  
 M. Krausz (*Canada*)
- 10:40 **Discussion**

**10:00 – 11:30** **Amsterdam Hall**

Symposium:

**Old Age Depression: Do we Need a Special Approach**

 Chairs: R. Heun (*United Kingdom*)  
 W. Maier (*Germany*)

- 10:00 **Old Age Depression: Does Distinct Pathophysiology Require a Different Approach to Treatment?**  
 R. Heun (*United Kingdom*)
- 10:20 **Distinction of Dementia and Depression in Various Stages of the Disease Processes**  
 W. Maier (*Germany*)
- 10:40 **Physical Comorbidity and Consequences for Mortality and Treatment**  
 R. Heun (*United Kingdom*)
- 11:00 **Clinical Pharmacological Management of Polypharmacy in Old Age Depression**  
 P. Baumann (*Switzerland*)
- 11:20 **Discussion**

**10:00 – 11:30** **La Paz Hall**

Early Career Psychiatrists:

**Conversations – Tackling Suicide Where There are Too Few Psychiatrists**

 Chairs: K. Koelkebeck (*Germany*)  
 S. Galderisi (*Italy*)

**Tackling Suicide where there are too few Psychiatrists**  
 V. Patel (*India*)

**11:30 – 11:45**
**Short Break**
**11:45 – 12:30** **Auditorium A**

Plenary:

**Adversities in Childhood and their Impact on Mental Health Across the Life Course**

 Chair: S. Galderisi (*Italy*)

- 11:45 **Adversities in Childhood and their Impact on Mental Health across the Life Course**  
 S. Pollak (*USA*)

**12:30 – 13:15**
**Break, e-Poster Viewing, e-Poster Walks & Exhibition**
**13:15 – 14:00** **Roma Hall**

State-of-the-Art:

**The Concept of Bipolar Disorder**

 Chair: J.N. Beezhold (*United Kingdom*)

- 13:15 **The Concept of Bipolar Disorder**  
 A. Young (*United Kingdom*)

**14:00 – 14:45** **Roma Hall**

State-of-the-Art:

**Drinking Patterns we Should Accept While Reducing Harmful Alcohol Consumption**

 Chair: P. Gorwood (*France*)

- 14:00 **Drinking Patterns we should Accept while Reducing Harmful Alcohol Consumption**  
 K. Mann (*Germany*)

**13:15 – 14:45**  **Berlín Hall**

Symposium:

**Relapse Prevention in Addiction – From Bench to Bedside**

 Chairs: F. Kiefer (*Germany*)

 A. Lingford-Hughes (*United Kingdom*)

**13:15 Neurobiology and Principles of Relapse Prevention Treatment in Alcohol Addiction**

 A. Lingford-Hughes (*United Kingdom*)

**13:35 Role of Inhibitory Processes in Relapse Prevention Treatment**

 G. Rudio (*Spain*)

**13:55 From Genes to Treatment: The Effect of Polymorphisms in Neurotransmitter Systems on Addictive Behaviour, Neural Response and Relapse**

 P. Bach (*Germany*)

**14:15 From Bench to Bedside: Two New Concepts Evaluated for Reducing Ethanol Consumption in Alcohol Use Disorders**

 B. Soderpalm (*Sweden*)

**14:35 Discussion**
**13:15 – 14:45** **Madrid Hall**

Joint Symposium:

**Making Medicines Out of Illicit Drugs – ECNP Symposium Hosted by EPA**

 Chairs: W. van den Brink (*The Netherlands*)

 G. Dom (*Belgium*)

**13:15 Can Ecstasy Treat the Agony of PTSD?**

 M. Mithoefer (*USA*)

**13:45 Treatment of Heroin Dependence with Ibogaine**

 A. Schellekens (*The Netherlands*)

**14:15 Cannabinoids: From Risk Factor to Treatment Option in Schizophrenia**

 M. Leweke (*Germany*)

**13:15 – 14:45** **Londres Hall**

Joint Symposium:

**Europe Meets Asia – Commonalities, Differences and Future Perspectives on Postgraduate Training in Psychiatry – Joint Symposium with AFPA**

 Chairs: W. Gaebel (*Germany*)

 S. Kanba (*Japan*)

**13:15 The European Perspective**

 W. Gaebel (*Germany*)

**13:30 New Specialist System of Residency in Psychiatry**

 S. Kanba (*Japan*)

**13:45 The Trainee Perspective**

 M. Phanasathit (*Thailand*)

**14:00 The Trainee Perspective**

 O. Andlauer (*United Kingdom*)

**14:15 Discussion**
**13:15 – 14:45** **Paris Hall**

Symposium:

**Diagnostic Process in Psychiatry**

 Chairs: L. Küey (*Turkey*)

 M. Musalek (*Austria*)

**13:15 Philosophical and Humanistic Basis of Diagnostic Process**

 M. Musalek (*Austria*)

**13:35 Neuroscientific Basis of Diagnostic Process**

 C. Montag (*Germany*)

**13:55 Transcultural Issues in Diagnostic Process**

 M. Kastrup (*Denmark*)

**14:15 Interview and Therapeutic Rapport in Diagnostic Process**

 L. Küey (*Turkey*)

**14:35 Discussion**

**13:15 – 14:45** **Amsterdam Hall**

Workshop:

**How Should Psychopharmacotherapy be Learned by Residents in Psychiatry –  
 Proposals of Sychopharmacology Curricula**

 Chairs: P. Baumann (*Switzerland*)  
 G. Laux (*Germany*)

- 13:15 **The Present Situation of Psychopharmacology Teaching Suggests the Need for a European Curriculum**  
 P. Baumann (*Switzerland*)
- 13:25 **A European Psychopharmacology Curriculum: The Young Psychiatrist's Point of View**  
 M. Spies (*Austria*)
- 13:35 **Proposal for a Model Psychopharmacology Curriculum for Psychiatric Residents in Germany**  
 G. Laux (*Germany*)
- 13:45 **The New Neuroscience Based Nomenclature of Neuropsychotropic Drugs: A Chance for a better Understanding and Teaching of Clinical Psychopharmacology**  
 H. Möller (*Germany*)
- 13:55 **Psychopharmacology During Residents' Training: The Role of Scientific Societies**  
 P.M. Llorca (*France*)
- 14:05 **Discussion**

**13:15 – 14:45** **EECP** **La Paz Hall**

Early Career Psychiatrists:

**EFPT/ECPC-EPA Symposium – Research by Trainees and Early Career Psychiatrists**

 Chairs: M. Casanova Dias (*United Kingdom*)  
 M.M. Carrasco (*Spain*)

- 13:15 **Brain Drain Project**  
 M. Pinto da Costa (*Portugal*)
- 13:30 **How EFPT Trainee-led Cross-national Research can change Training in Psychiatry**  
 L. De Picker (*Belgium*)
- 13:45 **How EFPT Trainee-led Cross-national Research can change Training in Psychiatry**  
 T. Mogren (*Sweden*)
- 14:00 **Burnout Study**  
 N. Jovanovic (*Croatia*)
- 14:15 **mPIVAS**  
 M. Rojnic Kuzman (*Croatia*)
- 14:30 **Discussion**

**14:45 – 15:15**
**Coffee Break, e-Poster Viewing & Visit the Exhibition**

**15:15 – 16:45** **Roma Hall**

## Symposium:

**Physical Activity for People with Psychotic Disorders: Realities and Prospects**

 Chairs: J. L. Ayuso-Mateos (*Spain*)  
 P. Falkai (*Germany*)

- 15:15 **Clinical and Neurobiological Effects of Aerobic Endurance Training in Multi-Episode Schizophrenia Patients**  
 P. Falkai (*Germany*)
- 15:35 **Studies on PA in Schizophrenia: What Did We Learn? What is Effective?**  
 G. de Girolamo (*Italy*)
- 15:55 **Feasibility and Effectiveness of Aerobic Exercise Training Interventions in Schizophrenia**  
 K. Katriona (*Germany*)
- 16:15 **Adopting and Maintaining Physical Activity Behaviour in People with Severe Mental Illness: The Importance of Autonomous Motivation**  
 S. Rosenbaum (*Australia*)
- 16:35 **Discussion**

**15:15 – 16:45** **Berlin Hall**


## Symposium:

**E-Psychiatry: From Acceptability to Effectiveness!**

 Chairs: M. Wise (*United Kingdom*)  
 D. Mucic (*Denmark*)

- 15:15 **A Study on the Effectiveness of E-Mental Health in the Treatment of Psychosis: Looking to Recovery**  
 F. Gucci (*Italy*)
- 15:35 **The Acceptability of Web-Care for Patients with Major Depressive Disorder**  
 M. Ladea (*Romania*)
- 15:55 **The Impact of E-Mental Health on Prevention and Early Detection of Illness**  
 D. Hilty (*USA*)
- 16:15 **Digital Healthcare: Fools Gold or a Promised Land?**  
 M. Wise (*United Kingdom*)
- 16:35 **Discussion**

**15:15 – 16:45** **Madrid Hall**

## Symposium:

**Culture-Society Bound Psychopathology**

 Chairs: W. Gaebel (*Germany*)  
 T. Kato (*Japan*)

- 15:15 **Workaholism – Mental Disorder or highly honorable Behavior**  
 M. Musalek (*Austria*)
- 15:30 **Future Components of Psychopathology**  
 W. Gaebel (*Germany*)
- 15:45 **Hikikomori and Modern-Type Depression in Japan**  
 T. Kato (*Japan*)
- 16:00 **International Research on Social Withdrawal**  
 A. Teo (*USA*)
- 16:15 **The Asian Perspective**  
 S. Kanba (*Japan*)
- 16:30 **Discussion**

**15:15 – 16:45** **Londres Hall**

## Debate:

**Personality Disorders: Dimensions Instead of Subtypes**

 Chair: M. Kastrup (*Denmark*)

 15:15 **The Advantages of a Classification of Personality Disorder Based on Severity**  
 P. Tyrer (*United Kingdom*)

 16:00 **Con**  
 S. Herpertz (*Germany*)

**15:15 – 16:45** **Paris Hall**

## Symposium:

**Biological Markers of Short-Term and Long-Term Treatment Outcome in Mental Disorders**

 Chairs: J. Samochowiec (*Poland*)  
 A. Szulc (*Poland*)

 15:15 **Neuroimaging Findings Predating the Onset of Psychosis and their Impact on Later Treatment Outcome**  
 S. Borgwardt (*Switzerland*)

 15:35 **Brain Glutamate Levels and Antipsychotic Response in Schizophrenia**  
 A. Egerton (*United Kingdom*)

 15:55 **Biochemical and Genetic Markers in Patients with Alcohol Dependence and Affective Disorders and Their Correlation with Alcohol Intake**  
 U. Preuss (*Germany*)

 16:15 **Potential Relationship between Inflammatory Markers, Neuroimaging Findings and Treatment Response in Depression**  
 A. Szulc (*Poland*)

 16:35 **Discussion**
**15:15 – 16:45** **Amsterdam Hall**

## Workshop:

**Schizophrenia Research: The Necessary Link Between Psychopathology and Clinical Neuroscience**

 Chairs: M.L. Figueira (*Portugal*)  
 S. Galderisi (*Italy*)

 15:15 **From Griesinger to DSM-V: Do we need the Diagnosis of Schizophrenia?**  
 A. Erfurth (*Austria*)

 15:25 **Role of Psychopathology in Elucidating the Underlying Neural Mechanisms**  
 F. Oyeboode (*United Kingdom*)

 15:35 **The Role of Cognition in the Psychopathology of Schizophrenia: Assessment and Treatment Options**  
 G. Sachs (*Austria*)

 15:45 **Negative Symptoms in Relation to Brain Changes in Schizophrenia**  
 E. Pomarol-Clotet (*Spain*)

 15:55 **Discussion**



15:15 – 16:45

La Paz Hall

Oral Communications:

**Geriatric Psychiatry**

Chair: R. Heun (*United Kingdom*)

- 15:15 **A Quality Improvement Intervention in Geriatric Psychiatry Care: Results of a Pre-Post Design Study**  
E. Albuquerque (*Portugal*)
- 15:26 **Association Between Physical Frailty and Cognition in Late-Life Depression**  
M. Arts (*The Netherlands*)
- 15:37 **Association Between Physical Frailty and Inflammation in Late-Life Depression**  
M. Arts (*The Netherlands*)
- 15:48 **Antidepressants and Mortality Risk in a Dementia Cohort-Data from SveDem, the Swedish Dementia Registry**  
D. Enache (*Sweden*)
- 15:59 **Validity of the Geriatric Depression Scale-30 against the Gold Standard Diagnosis of Depression in Older Age: The GreatAGE Study**  
M. Lozupone (*Italy*)
- 16:10 **Specific Personality Changes in Subjects with MCI and Mild Dementia are Associated with Cerebral Alzheimer's Pathology as Measured by CSF Biomarkers**  
D. Tautvydaitė (*Switzerland*)
- 16:21 **Diuretic Medication use Reduces Incident Dementia Risk: A Meta-Analysis of Prospective Studies**  
P. Tully (*Australia*)



EUROPEAN PSYCHIATRIC ASSOCIATION

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

Madrid, Spain 12-15 March 2016  
[www.epa-congress.org](http://www.epa-congress.org)

TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY

## INDEX OF AUTHORS

## INDEX OF AUTHORS

A		Buehl A.	61
Ahuja A.	39	Brunner R.	38
Albuquerque E.	104	Buwalda V.	93
Aleman A.	73	C	
Alves-dos-Reis T.	46	Cahn W.	81
Andlauer O.	83, 97	Cailhol L.	47
Apter A.	43, 88	Caldas de Almeida J.	80
Aragona M.	82	Carli V.	29
Arensxman E.	59	Carrasco M.M.	23, 44, 52, 87, 99
Arous A.	76	Casanova Dias M.	99
Arranz B.	54	Castroman J.L.	53
Arts M.	104	Cealicu Toma F.	40
Asherson P.	25, 90	Cohen Y.	24, 50, 65
Ayuso-Mateos J. L.	100	Cordes J.	47
B		Courtenay K.	26
Baca-Garcia E.	29	Courtet P.	29
Bach P.	96	Craig T.J.	44
Bailey S.	36, 44	Cuesta M.	45
Baldwin D.	61	D	
Barbosa A.	24, 67	Da Silva A.G.	92
Baron E.	63	Davidson M.	65
Bates P.	83	Dayan Riva A.	35
Batisse A.	34	De Backer L.	63, 72
Baumann P.	94, 98	de Girolamo G.	32, 52, 100
Becker T.	35	Deiana V.	34, 35
Beezhold J.N.	42, 78, 80, 95	de Lijster J.	32
Berna F.	76	de Mendonça Lima C.A.	60
Bernardo Arroyo M.	76	Demetrovics Z.	46
Bernegger G.	30	Denzel D.	45
Bhugra D.	25, 31, 39, 44	De Picker L.	99
Bhui K.	93	Diefenbacher A.	24, 67
Bitter I.	37	Diego P.	31
Blasco-Fontecilla H.	53	Dierks T.	51
Bobes J.	37, 87	DiPetta G.	30
Bocking C.	71	Doerr-Zegers O.	82
Boiko A.	76	Dollfus S.	63, 89
Bonal Giménez C.	47	Dom G.	33, 70, 72, 96
Borgwardt S.	30, 102	Draganski B.	79
Botis A.C.	54	Drake R.	35
Brambillà P.	38	Dumitru M.M.	47
Brittlebank A.	70		

**E**

Ebisch S.	73
Ebner-Priemer U.	90
Egerton A.	102
Egger S.	55
El-Missiry A.	76
Enache D.	104
Erfurth A.	103
Erkoreka L.	47
Evans-Lacko S.	65, 80
Ezquiaga I.	34

**F**

Falkai P.	75, 81, 92, 100
Fananas L.	60
Fañanás L.	40
Faurholt-Jepsen M.	31
Favaro A.	32
Ferrari S.	67
Figueira M.L.	103
Fiorillo A.	38, 77
Fortuna L.	68
Frangou S.	50, 90
Fuste M.	45

**G**

Gaebel W.	23, 24, 30, 36, 41, 44, 50, 63, 65, 74, 80, 87, 97, 101
Galderisi S.	23, 30, 37, 42, 51, 63, 79, 94, 95, 103
Galindo L.	76
García-Portilla Gonzalez M.P.	46, 63
Gargot T.	70
Gaillard J.	60
Georgescu D.	24
Giacco D.	41, 83
Goethals K.	25, 62
Gonzalez-Blanco L.	46
Gorwood P.	60, 95
Graef-Calliess I.T.	25, 93
Gucci F.	101
Gureje O.	74
Gusmão R.	59
Gutiérrez Fraile M.	92

**H**

Hajek T.	79
Hakala M.	54

Hall I.	83
Hall T.	39
Handest P.	26
Hanon C.	78
Haro J.M.	23, 80
Hauth I.	75
Hegerl U.	59
Heinz A.	33, 71, 93
Henry C.	50
Henze R.	38
Hermans M.	87
Herpertz S.	102
Herrman H.	79
Heun R.	60, 94, 104
Hilty D.	38, 101
Hobl B.	61
Hohagen F.	48, 69, 91
Holubova M.	76
Hopkins C.	35
Hopwood M.	92
Horacek J.	79
Hou Z.	45
Huhtaniska S.	54
Huss M.	34

**I**

Iancu I.	61
Isohanni M.	49
Isometsa E.	43
Ivanovic-Zuvic F.	92

**J**

Jansen J.	72
Jimenez-Trevino L.	47
Johnson B.	24, 35, 65, 83
Jovanovic N.	48, 91, 99
Jung D.	76

**K**

Kai L.	76
Kaiser S.	63
Kanba S.	97, 101
Kanellopoulos A.	70
Karakula-Juchnowicz H.	54, 90, 91
Kashdan T.	48
Kasper S.	37
Kastrup M.	44, 81, 91, 93, 97, 102
Kato T.	101

Katriona K.	100
Katschnig H.	75
Kaufmann T.	30
Kazakova O.	41, 67
Kebir O.	60
Kiefer F.	96
Killaspy H.	35
Kircher T.	89
Klemperer D.	36
Knapp M.	24, 50
Koelkebeck K.	67, 94
Koopmann A.	72
Koponen H.	49
Korostiy V.	66
Kosidou K.	64
Koutsouleris N.	81
Kovess-Masfety V.	79
Krausz M.	33, 39, 93
Krug I.	45
Krzysztof K.	38
Kucharska-Mazur J.	34
Küey L.	66, 79, 93, 97
Kurimay T.	36, 46
Kuyken W.	48
Kyriakopoulos M.	45

**L**

Labad J.	92
Ladea M.	101
Larøi F.	26
Lasalvia A.	65
Latham R.	62
Lauber C.	24
Laura F.	77
Laux G.	98
Lee T.Y.	54
Leweke M.	96
Lingford-Hughes A.	96
Llorca P.M.	98
Lozupone M.	104
Luciano M.	80
Lund H.	40
Lydall G.	48

**M**

Madeira L.	82
Mahdavi S.	68
Maier W.	94
Maj M.	23, 66

Mann J.J.	43
Mann K.	64, 95
Mansuri Z.	40, 76
Manzhurtsev A.	45
Marasco D.	77
Mateos R.	52
Mattei G.	34, 67
Mayol J.	31
McCarthy J.	62, 90
McIntyre J.	36
McNicholas F.	52
Medici C.R.	40
Melle I.	51
Mendonça D.	78
Meyer T.	36
Michel Llorca P.	40
Mina A.	68
Misiak B.	54
Mithoefer M.	96
Moggi F.	33
Mogren T.	99
Möller H.	98
Möller-Leimkühler A.M.	75
Montag C.	97
Montoro R.	39
Morales G.	80
Morgan V.	49
Morrissey C.	62
Moscoso A.	91
Mrizak J.	77
Mucci A.	63, 88
Mucic D.	38, 101
Muijen M.	24, 66, 80
Murray R.	32
Musalek M.	26, 30, 51, 82, 97, 101
Myin-Germeyns I.	92

**N**

Navinés R.	34
Nedopil N.	25
Neil A.	46
Niemelä S.	34
Nikolic Lalic S.	64
Nobile M.	38
Northoff G.	73
Nosarti C.	38
Notredame C.	31

**O**

Okkels N.	47
Olie E.	88
Oliveira-Maia A.	45
Oliveira P.	78
Oquendo M.A.	43
Orrell M.	52
Orsolini L.	70, 72
Ostinelli E.G.	54
Ouanes S.	45
Oude Voshaar R.	52
Oyebode F.	103

**P**

Palao Vidal D.	54
Papanti D.	72
Patel R.	40
Patel V.	71, 94
Paus T.	79
Pavlovic Z.	40
Pekelharing E.	90
Pelissolo A.	61
Peña-Rey I.	80
Perera B.	26
Perez V.	59
Peters E.	66
Phanasathit M.	97
Pikalov A.	77
Pinto da Costa M.	31, 70, 78, 87, 99
Pollak S.	95
Pomarol-Clotet E.	103
Popovic A.	77
Preuss U.	102
Priebe S.	41
Pūras D.	23

**Q**

Qureshi H.	31
------------	----

**R**

Raballo A.	26
Ramalheira C.	30
Ramos Perdigues S.	54
Ramos-Quiroga J.	25, 37, 90
Ramoz N.	60
Rathod M.	40, 77
Reed G.	74
Reichelt K.L.	90

Reneses B.	31
Richard A.	46
Richards D.	47
Riecher-Rössler A.	79, 92
Riese F.	60, 78
Roca Bennasar M.	92
Rocca P.	88
Rojnic Kuzman M.	64, 99
Rosenbaum S.	100
Rössler W.	35, 66, 72
Roux P.	45
Rubinstein K.	49
Rudio G.	96
Ryan J.F.	23
Rymaszewska J.	68

**S**

Sachs G.	88, 89, 103
Saeed S.	93
Sáiz Martínez P.A.	29
Samochowiec J.	102
Sánchez A.	55
Santosh P.	53
Sarchiapone M.	29, 53
Sartorius N.	32, 44, 65
Schellekens A.	72, 96
Schmahl C.	88
Schmidt-Kraepelin C.	66
Schouler-Ocak M.	25, 93
Schwager H.	93
Seppala J.	49
Serafini G.	68
Severance E.	90
Shiers D.	50
Singh S.	52
Sisek-Šprem M.	55
Sobanski E.	25, 90
Soderpalm B.	96
Sommers I.	89
Soni S.	83
Sönmez E.	70
Spies M.	98
Stanghellini G.	51, 69, 82, 91
Stein D.	74
Stella E.	40
Stenz L.	60
Stoppe G.	32, 52, 64
Strik W.	89
Sukasem C.	68

Sutaria A.	40
Suzuki K.	31
Szulc A.	102
Szymona K.	55

**T**

Takeda M.	44
Tautvydaitė D.	104
Teixeira L.	78
Telles D.	67
Teo A.	101
Thorell L.H.	53
Tort Herrando V.	62
Tost H.	81
Tremblay M.	50
Tremmery S.	53
Tully P.	104
Tunç S.	68
Tuomainen H.	52
Tyrer P.	69, 102

**U**

Usall-Rode J.	92
---------------	----

**V**

Valenti E.	78
Vallon P.	75
van den Brink W.	64, 96
van der Gaag R.J.	64, 75, 79, 87
Van Eenennaam F.	50
van Nierop M.	66
van Wijngaarden-Cremers P.J.M.	33
Varandas P.	30
Vargas M.	55
Vasileva A.	41
Veerman S.	55
Vidal Mariño C.	47
Viltrakyte I.	70
Völlm B.	62
Volpe U.	77

**W**

Wagner G.	30, 73
Wahlbeck K.	41
Waldinger M.	42, 64
Walther S.	30
Wang H.	77
Ward P.	69
Wasserman D.	24, 36, 53, 69, 71
Weiss C.	55
Wessely S.	75
Wieck A.	46
Wilkinson S.	51
Wilson-Jones C.	31
Winiewicz D.	68
Wise M.	101
Wong W.	41
Wunderink L.	81
Wykes T.	42
Wyss C.	45

**Y**

Yoshimasu K.	34
Young A.	95

**Z**

Zalsman G.	36, 64
------------	--------

[illegible]

# 24<sup>th</sup> EUROPEAN CONGRESS OF PSYCHIATRY

**Madrid, Spain 12-15 March 2016**  
**[www.epa-congress.org](http://www.epa-congress.org)**

TOWARDS A COMMON LANGUAGE  
IN EUROPEAN PSYCHIATRY

# COMPANY AND EXHIBITION GUIDE

Join Us on  
Social Media

Network,  
Collaborate and  
Stay Up-to-Date



EUROPEAN PSYCHIATRIC NETWORK | [europsychiatric.com](http://europsychiatric.com)

## ACKNOWLEDGMENTS

EPA wishes to express its gratitude for the contribution and support of the following healthcare industries:

### PLATINUM SPONSOR



### GOLD SPONSOR



### SILVER SPONSOR



### SPONSORS




### EXHIBITORS



# INDUSTRY SUPPORTED SATELLITE SYMPOSIA

SUNDAY, 13 MARCH 2016 | 13:15 – 14:45

THE CHALLENGE OF TREATING DEPRESSION IN THE PRESENCE OF COMORBIDITIES

INDUSTRY SESSION SUPPORTED BY 

**Chairs:** Julio Bobes, *Spain*  
Hans Jürgen Möller, *Germany*

- 13:15 – 13:20    **Introduction**  
Julio Bobes, *Spain*
- 13:20 – 13:45    **The Burden of Somatic and Neurologic Comorbidities in Depression**  
Riccardo Torta, *Italy*
- 13:45 – 14:10    **Comorbid Anxiety Disorders and Major Depressive Disorder: Where do we Stand?**  
Hans-Jürgen Möller, *Germany*
- 14:10 – 14:35    **Agomelatine: A Different Management of Depressed Patients with Comorbidity**  
Philip Gorwood, *France*
- 14:35 – 14:45    **Conclusion**  
Hans-Jürgen Möller, *Germany*

SUNDAY, 13 MARCH 2016 | 13:15 – 14:45

ADULT ADHD – IN YOUR CLINICAL PRACTICE

INDUSTRY SESSION SUPPORTED BY 

- 13:15 – 13:20    **ADHD in Adults**  
Hilary Jones, *United Kingdom*
- 13:20 – 13:40    **The Differential Diagnosis of Adult ADHD**  
Larry Klassen, *Canada*
- 13:40 – 14:00    **Panel-audience Discussion Forum: Recognising and Diagnosing Adult ADHD**  
Larry Klassen, *Canada*  
Greg Mattingly, *USA*  
Toni Ramos, *Spain*  
Susan Young, *United Kingdom*
- 14:00 – 14:20    **Treating Adult ADHD – Elvanse Adult®**  
Greg Mattingly, *USA*
- 14:20 – 14:40    **Panel-audience Discussion Forum: Sharing Clinical Practice Experience: Managing and Treating Adult ADHD**  
Larry Klassen, *Canada*  
Greg Mattingly, *USA*  
Toni Ramos, *Spain*  
Susan Young, *United Kingdom*
- 14:40 – 14:45    **Closing Comments**  
Hilary Jones, *United Kingdom*

MONDAY, 14 MARCH 2016 | 13:15 – 14:45

MANAGEMENT OF AGITATION IN THE 21<sup>ST</sup> CENTURY

INDUSTRY SESSION SUPPORTED BY 

**Chair:** Eduard Vieta, *Spain*

**International Agitation Consensus: A New Paradigm**  
Eduard Vieta, *Spain*

**Let's Give Voice to Patients with Agitation**  
Andrea Fagiolini, *Italy*

**A New Clinical Approach Based on Therapeutic Alliances**  
Andreas Erfurth, *Austria*


satellite symposium

# Adult ADHD – in your clinical practice

PLEASE JOIN US

Sunday 13<sup>th</sup> March 2016  
13:15 to 14:45  
Madrid Hall

- 13:15-13:20 **ADHD in adults**  
Dr. Hilary Jones, UK
- 13:20-13:40 **The differential diagnosis of adult ADHD**  
Dr. Larry Klassen, Canada
- 13:40-14:00 **Panel-audience discussion forum**  
*Recognising and diagnosing adult ADHD*  
Dr. Larry Klassen, Canada  
Dr. Greg Mattingly, USA  
Dr. Toni Ramos, Spain  
Prof. Susan Young, UK
- 14:00-14:20 **Treating adult ADHD – Elvanse Adult®**  
Dr. Greg Mattingly, USA
- 14:20-14:40 **Panel-audience discussion forum**  
*Sharing clinical practice experience:  
managing and treating adult ADHD*  
Panel: As above
- 14:40-14:45 **Closing comments**  
Dr. Hilary Jones, UK



## ELVANSE ADULT® ▼ (lisdexamfetamine dimesylate) 30 mg, 50 mg and 70 mg capsules, hard.

**PRESCRIBING INFORMATION** (Please refer to full Summary of Product Characteristics (SmPC) before prescribing.)

**Uses:** Elvanse Adult is indicated as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Elvanse Adult is not indicated in all adult patients and the decision to use the medicinal product must take into consideration the profile of the patient, including a thorough assessment of the severity and chronicity of the patient's symptoms, the potential for abuse, misuse or diversion and clinical response to any previous pharmacotherapies for the treatment of ADHD. Treatment must be under the supervision of a specialist in behavioural disorders.

**Dosage and Administration:** The starting dose is 30 mg taken once daily in the morning. The dose may be increased by 20 mg increments, at approximately weekly intervals. Elvanse Adult should be administered orally at the lowest effective dosage. The maximum recommended dose is 70 mg/day. Patients with severe renal insufficiency should not exceed a maximum daily dose of 50 mg/day. Further dose reduction should be considered in patients on dialysis. **Administration:** Elvanse Adult may be taken with or without food and swallowed whole, or the capsule opened and the entire contents emptied and mixed with soft food such as yoghurt or in a glass of water or orange juice. If the contents include any compacted powder, a spoon may be used to break apart the powder. The contents should be stirred until completely dispersed. The patient should consume the mixture of soft food or liquid immediately; it should not be stored.

**Long-term Use:** Pharmacological treatment of ADHD may be needed for extended periods. The physician who elects to use Elvanse Adult for extended periods (over 12 months) should re-evaluate the usefulness of Elvanse Adult at least yearly, and consider trial periods off medication to assess the patient's functioning without pharmacotherapy.

**Contraindications:** Hypersensitivity to sympathomimetic amines or any of the excipients; concomitant use of monoamine oxidase inhibitors or within 14 days after MAOI treatment, hyperthyroidism or thyrotoxicosis, agitated states, symptomatic cardiovascular disease, advanced arteriosclerosis, moderate to severe hypertension, glaucoma.

**Warnings and Precautions for Use:** Stimulants including Elvanse Adult have a potential for abuse, misuse or diversion that physicians should consider when prescribing these products. The risk of misuse may be greater in adults (especially young adults) than in paediatric use. Stimulants should be prescribed cautiously to patients with a history of substance abuse or dependence. Monitor cardiovascular status carefully as sudden deaths, strokes, and myocardial infarction have been reported in adults taking stimulant

drugs at usual doses for ADHD. All patients should be monitored for changes in heart rate and blood pressure as stimulant medications cause a modest increase in average blood pressure and heart rate. Cardiomyopathy has been reported with Elvanse Adult, all patients should be assessed for the presence of cardiac disease. Monitor psychiatric status as treatment may exacerbate symptoms of behaviour disturbance and thought disorder in patients with pre-existing psychotic disorders. Particular care should be taken in using stimulants to treat ADHD patients with comorbid bipolar disorder because of concern for possible induction of mixed/manic episode. Stimulants may cause aggressive behaviour or hostility. Patients beginning treatment for ADHD should be monitored for the appearance of or worsening of aggressive behaviour or hostility. Stimulants have been reported to exacerbate tics, Tourette's syndrome, have been associated with weight loss, and may lower the convulsive threshold, and appropriate monitoring should be conducted. Difficulties with accommodation and blurring of vision have been reported with stimulant treatment. Elvanse Adult should be used with caution in patients who use other sympathomimetic drugs. The least amount of Elvanse Adult feasible should be prescribed or dispensed in order to minimise the risk of possible overdose by the patient.

**Interactions:** Extended-release guanfacine, extended-release venlafaxine, ascorbic acid and other agents and conditions that acidify urine, sodium bicarbonate and other agents that alkalise urine, monoamine oxidase inhibitors, serotonergic drugs, antihypertensives, narcotic analgesics, chlorpromazine, haloperidol, lithium carbonate. See SmPC for further details.

**Pregnancy and Lactation:** Not recommended.

**Driving:** Caution is advised.

**Adverse Effects:** Very common: decreased appetite, insomnia, dry mouth, headache. Common: agitation, anxiety, libido decreased, psychomotor hyperactivity, bruxism, dizziness, restlessness, tremor, tachycardia, palpitation, dyspnoea, diarrhoea, constipation, upper abdominal pain, nausea, hyperhidrosis, erectile dysfunction, irritability, fatigue, feeling jittery, blood pressure increased, weight decreased. Consult SmPC in relation to less common side effects.

**Pharmaceutical Precautions:** Store below 25°C. **Legal Category:** Prescription Only Medicine.

**Product Licence Numbers:** 30 mg: PL 08081/0059, 50 mg: PL 08081/0060, 70 mg: PL 08081/0061.

**NHS Cost** (for 28 capsules) 30 mg: £58.24, 50 mg: £68.60, 70 mg: £83.16.

**Date of Revision:** August 2015.

**Name and Address of MA Holder:** Shire Pharmaceutical Contracts Limited, Hampshire International Business Park, Chineham, Basingstoke, Hampshire RG24 8EP, United Kingdom. Tel: 0800 055 6614. Email: medinfo@shire.com. Further information is available on request. ELVANSE ADULT is a registered trade name.

Safety information, including adverse events, must be communicated to Shire by e-mail to this address [globalpharmacovigilance@shire.com](mailto:globalpharmacovigilance@shire.com) or by phone +34 915500691, or by fax +34 917917108.

La información de seguridad, incluidos los eventos adversos deben comunicarse a Shire mediante correo electrónico a la dirección [globalpharmacovigilance@shire.com](mailto:globalpharmacovigilance@shire.com) o por teléfono +34 915500691, o por fax +34 917917108.

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system found under section 4.8 of the SmPC.

▼ Este medicamento está sujeto a seguimiento adicional, es prioritaria la notificación de sospechas de reacciones adversas asociadas a este medicamento.

Elvanse Adult® (lisdexamfetamine dimesylate) is approved in Europe in the United Kingdom, Sweden (tradename: Elvanse Vuxen®) and Denmark (tradename: Aduvanz®). Lisdexamfetamine dimesylate is also licensed for use in adults with ADHD in Switzerland, Israel, Canada, Brazil and Australia.

Elvanse Adult® (lisdexamfetamine dimesylate) solo está autorizado en Europa en el Reino Unido, Suecia (nombre comercial: Elvanse Vuxen®) y Dinamarca (nombre comercial: Aduvanz®). Lisdexamfetamine dimesylate también está autorizado en adultos con TDAH en Suiza, Israel, Canadá, Brasil y Australia.

Elvanse Adult® is not licensed in Spain.

Elvanse Adult® no está autorizado en España.

The Summary of Product Characteristics is available at the booth.

La Ficha Técnica está disponible en el stand.

**Shire**

INTSP/C-APROM/NBU/15/0097b February 2016  
This meeting is organised and funded by Shire

**Elvanse Adult® ▼**  
(lisdexamfetamine dimesylate)  
capsules 30 • 50 • 70 mg

**Shire**

INTSP/C-APROM/NBU/15/0097b February 2016  
This meeting is organised and funded by Shire

**Elvanse Adult® ▼**  
(lisdexamfetamine dimesylate)  
capsules 30 • 50 • 70 mg

# Management of Agitation in the 21st Century

Chairman: *Dr. Eduard Vieta. Spain*

1. International Agitation Consensus: A new paradigm  
*Dr. Eduard Vieta. Spain*
2. Let's give voice to patients with agitation  
*Dr. Andrea Fagiolini. Italy*
3. A new clinical approach based on therapeutic alliances  
*Dr. Andreas Erfurth. Austria*

**Madrid, Spain**

Monday, 14th March 2016

13:15h - 14:45h. London Hall

Symposium organized during the 24th EPA Congress by 



Madrid, Spain  
March 12-15, 2016

Palacio Municipal  
de Congresos  
Hall C - Room Roma

**Sunday, March 13, 2016**  
**(13.15 – 14.45)**

Organized by



Satellite Symposium held during the  
24th European Congress of Psychiatry (EPA)

## Scientific programme

### The challenge of treating depression in the presence of comorbidities

Chairpersons

**J. Bobes** (Spain)

**H-J. Möller** (Germany)

Introduction

**J. Bobes** (Spain)

The burden of somatic and neurologic  
comorbidities in depression

**R. Torta** (Italy)

Comorbid anxiety disorders and major  
depressive disorder: where do we stand ?

**H-J. Möller** (Germany)

Agomelatine: a different management  
of depressed patients with comorbidity

**P. Gorwood** (France)

Conclusion

**H-J. Möller** (Germany)



## NOTES

[illegible]

## NOTES

[illegible]





EUROPEAN  
PSYCHIATRIC  
ASSOCIATION



TOGETHER  
FOR  
MENTAL  
HEALTH

JOIN US AT  
EPA 2017

25<sup>th</sup>  
EUROPEAN  
CONGRESS OF  
PSYCHIATRY

Florence, Italy  
1-4 April 2017

[www.epa-congress.org](http://www.epa-congress.org)

